ATE66693T1 - Rekombinante dns-sequenzen, diese enthaltende vektoren und verfahren zur verwendung derselben. - Google Patents

Rekombinante dns-sequenzen, diese enthaltende vektoren und verfahren zur verwendung derselben.

Info

Publication number
ATE66693T1
ATE66693T1 AT87900856T AT87900856T ATE66693T1 AT E66693 T1 ATE66693 T1 AT E66693T1 AT 87900856 T AT87900856 T AT 87900856T AT 87900856 T AT87900856 T AT 87900856T AT E66693 T1 ATE66693 T1 AT E66693T1
Authority
AT
Austria
Prior art keywords
methods
recombinant dna
dna sequences
vectors containing
use same
Prior art date
Application number
AT87900856T
Other languages
English (en)
Inventor
Richard Harris Wilson
Christopher Robert Bebbington
Original Assignee
Celltech Ltd
Univ Glasgow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10591815&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE66693(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltech Ltd, Univ Glasgow filed Critical Celltech Ltd
Application granted granted Critical
Publication of ATE66693T1 publication Critical patent/ATE66693T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT87900856T 1986-01-23 1987-01-23 Rekombinante dns-sequenzen, diese enthaltende vektoren und verfahren zur verwendung derselben. ATE66693T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB868601597A GB8601597D0 (en) 1986-01-23 1986-01-23 Nucleotide sequences
PCT/GB1987/000039 WO1987004462A1 (en) 1986-01-23 1987-01-23 Recombinant dna sequences, vectors containing them and method for the use thereof
EP87900856A EP0256055B1 (de) 1986-01-23 1987-01-23 Rekombinante dns-sequenzen, diese enthaltende vektoren und verfahren zur verwendung derselben

Publications (1)

Publication Number Publication Date
ATE66693T1 true ATE66693T1 (de) 1991-09-15

Family

ID=10591815

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87900856T ATE66693T1 (de) 1986-01-23 1987-01-23 Rekombinante dns-sequenzen, diese enthaltende vektoren und verfahren zur verwendung derselben.

Country Status (9)

Country Link
US (3) US5122464A (de)
EP (1) EP0256055B1 (de)
JP (1) JPH0732712B2 (de)
AT (1) ATE66693T1 (de)
AU (1) AU599081B2 (de)
CA (1) CA1338901C (de)
DE (1) DE3772485D1 (de)
GB (1) GB8601597D0 (de)
WO (1) WO1987004462A1 (de)

Families Citing this family (1143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) * 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
JPH01243989A (ja) * 1988-03-23 1989-09-28 Toyo Jozo Co Ltd グルタミン合成酵素の遺伝情報を有するｄｎａおよびその用途
GB8809129D0 (en) * 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5879936A (en) * 1988-04-18 1999-03-09 Aluguisse Holding A.G. Recombinant DNA methods, vectors and host cells
ATE129289T1 (de) * 1988-12-08 1995-11-15 Abbott Lab Verfahren zur induzierbaren genexpression unter verwendung eines dhfr-gens.
GB2237288A (en) * 1989-10-18 1991-05-01 Celltech Ltd Amplification of a heterologous gene in recombinant eukaryotic host cells
GB8924021D0 (en) * 1989-10-25 1989-12-13 Celltech Ltd Recombinant dna method and vectors for the use therein
US5747308A (en) * 1989-10-25 1998-05-05 Celltech Therapeutics Limited Recombinant DNA method
US5891693A (en) * 1990-01-25 1999-04-06 Alusuisse Holdings A.G. Recombinant DNA methods vectors and host cells
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5252523A (en) * 1991-10-09 1993-10-12 Corning Incorporated Bioabsorbable chlorophosphate glasses and bioabsorbable glass-polymer blends made therefrom
GB9209993D0 (en) 1992-05-08 1992-06-24 Munn Edward A Vaccines
GB9215834D0 (en) 1992-07-24 1992-09-09 Celltech Ltd Cell culture
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US5908623A (en) * 1993-08-12 1999-06-01 Cytotherapeutics, Inc. Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
ATE218893T1 (de) * 1993-08-12 2002-06-15 Neurotech Sa Biokompatible immunoisolatorische kapseln, die genetisch veränderte zellen enthalten
AU707440B2 (en) 1994-03-29 1999-07-08 Celltech Therapeutics Limited Antibodies against E-selectin
CA2204355C (en) 1994-11-02 2001-01-16 Gail Mandel Peripheral nervous system specific sodium channels, dna encoding therefor, crystallization, x-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
IL114615A0 (en) 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
WO1997038123A1 (en) * 1996-04-05 1997-10-16 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US5776746A (en) * 1996-05-01 1998-07-07 Genitope Corporation Gene amplification methods
WO1997046589A2 (en) 1996-06-07 1997-12-11 Neorx Corporation Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
EP1482031B1 (de) 1996-08-30 2015-10-28 Life Technologies Corporation Serumfreies Kulturmedium für Säugerzellen und seine Verwendung
US6083715A (en) * 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
US6242666B1 (en) * 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
DK1141028T3 (da) 1998-12-23 2010-05-25 Pfizer Humane monoklonale antistoffer til CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
DE60043051D1 (de) 1999-01-11 2009-11-12 Schering Corp Dafür kodierende polynukleotide. verwendungen
EP2357192A1 (de) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Menschliches alpha-Endokin und Verfahren zu seiner Verwendung
JP2002538167A (ja) * 1999-03-03 2002-11-12 バイオジェン インコーポレイテッド 脂質の代謝および貯蔵を調節する方法
JP4488579B2 (ja) * 1999-03-30 2010-06-23 日本たばこ産業株式会社 モノクローナル抗体の製造方法
DK1167537T3 (da) * 1999-03-30 2008-11-10 Japan Tobacco Inc Fremgangsmåde til fremstilling af et monoklonalt antistof
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
SK11672002A3 (sk) 2000-01-10 2002-12-03 Maxygen Holdings Ltd. Polypeptidový konjugát, spôsob jeho výroby, farmaceutický prostriedok s jeho obsahom a jeho použitie
DE60138364D1 (de) 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
EP2206720A1 (de) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albuminfusionsproteine
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US20060141455A1 (en) 2002-01-08 2006-06-29 Rhonda Hansen Gene products differentially expressed in cancerous breast cells and their methods of use
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
CA2413160A1 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
US6852510B2 (en) * 2000-07-03 2005-02-08 Gala Design Inc Host cells containing multiple integrating vectors
US20030224415A1 (en) * 2001-06-29 2003-12-04 Gala Design, Inc. Selection free growth of host cells containing multiple integrating vectors
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
JP2004506021A (ja) * 2000-08-11 2004-02-26 ファブリル　インコーポレイテッド Ｔ細胞媒介性病態を改変するための方法および組成物
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20020099183A1 (en) * 2000-08-23 2002-07-25 Pluschkell Stefanie Beate Process for the preparation of neutrophil inhibitory factor
EP2412384A1 (de) 2000-11-28 2012-02-01 MedImmune, LLC Verfahren zur Verabreichung/Dosierung von Anti-RSV-Antikörpern zur Prophylaxe und Behandlung
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
BRPI0116728B1 (pt) 2001-01-05 2018-10-30 Pfizer Inc. anticorpos para receptor de fator de crescimento i semelhante à insulina
EP2080771A3 (de) 2001-02-27 2010-01-06 Maxygen Aps Neue Interferon-betaartige Moleküle
WO2002098370A2 (en) * 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2002092017A2 (en) 2001-05-16 2002-11-21 Albert Einstein College Of Medicine Of Yeshiva University Human antipneumococcal antibodies from non-human animals
MXPA03010747A (es) 2001-05-25 2004-03-02 Human Genome Sciences Inc Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
BRPI0214168B8 (pt) 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
EP2261250B1 (de) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin Fusionsproteine
KR100982922B1 (ko) * 2002-01-17 2010-09-20 론자 바이올로직스 피엘씨 단백질을 생산할 수 있으며 무글루타민 배지에서 성장할 수있는 글루타민-요구성 인간세포
GB0200977D0 (en) * 2002-01-17 2002-03-06 Lonza Biologics Plc Glutamine-auxotrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium
JP2005523688A (ja) * 2002-01-18 2005-08-11 ブリストル−マイヤーズ　スクイブ　カンパニー タンパク質チロシンキナーゼおよび／またはタンパク質チロシンキナーゼ経路と相互作用する化合物の活性を予測するためのポリヌクレオチドおよびポリペプチドの同定
AU2003244515A1 (en) 2002-02-07 2003-09-02 Novozymes Delta Limited Albumin-fused anti-angiogenesis peptides
ATE423217T1 (de) * 2002-03-01 2009-03-15 Siemens Healthcare Diagnostics Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten
US7473534B2 (en) * 2002-03-01 2009-01-06 Siemens Healthcare Diagnostics Inc. Assays for cancer patient monitoring based on levels of epidermal growth factor receptor (EGFR) extracellular domain (ECD) analyte, alone or in combination with other analytes, in body fluid samples
CA2480052A1 (en) * 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
GB0207533D0 (en) 2002-04-02 2002-05-08 Oxford Glycosciences Uk Ltd Protein
US7371383B2 (en) 2002-04-12 2008-05-13 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
BR0309254A (pt) 2002-04-12 2005-03-01 Medarex Inc Uso de um anticorpo anti-ctla-4
US7217796B2 (en) 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
AU2003280130B2 (en) 2002-06-28 2009-06-11 Centocor, Inc. Mammalian CH1 deleted mimetibodies, compositions, methods and uses
GB0216648D0 (en) * 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
PT1534736E (pt) 2002-08-10 2010-09-07 Univ Yale Antagonistas do receptor nogo
WO2004022097A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
ZA200502612B (en) 2002-10-08 2007-07-25 Rinat Neuroscience Corp Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
SI2301965T1 (sl) 2002-10-16 2015-07-31 Purdue Pharma L.P. Protitelesa, ki vežejo celično- povezan CA 125 / O722P in metode uporabe le-teh
CN101928344B (zh) 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
CN101014364B (zh) 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
DK1585546T3 (da) 2002-12-30 2008-12-08 Biogen Idec Inc KIM- 1- Antagonister og Brug til at Modulere Immunsystem
EP1585815A4 (de) * 2003-01-21 2006-02-22 Bristol Myers Squibb Co Ein neues acyl-coenzym a, monoacylglycerin-acyltransferase-3 (mgat3), codierendes polynukleotid sowie verwendungen davon
AU2004213053C1 (en) 2003-02-20 2009-07-16 Seagen Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
WO2004085648A2 (en) 2003-03-19 2004-10-07 Biogen Idec Ma Inc. Nogo receptor binding protein
JP4764818B2 (ja) 2003-04-11 2011-09-07 メディミューン，エルエルシー 組換えｉｌ−９抗体およびその使用
KR100872210B1 (ko) 2003-04-23 2008-12-05 메다렉스, 인코포레이티드 인터페론 알파 수용체-1 (ｉｆｎａｒ-1)에 대한 인체화항체
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
EP1644408A1 (de) * 2003-07-15 2006-04-12 Barros Research Institute Eimeria tenella-antigen zur immuntherapie von kokzidiose
US20050058658A1 (en) * 2003-07-15 2005-03-17 Barros Research Institute Compositions and methods for immunotherapy of human immunodeficiency virus (HIV)
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
EP1660186B1 (de) 2003-08-18 2013-12-25 MedImmune, LLC Humanisierung von antikörpern
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
PT1694360E (pt) 2003-11-04 2010-12-13 Novartis Vaccines & Diagnostic Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento de doenças auto-imunes e inflamatórias e da rejeição ao transplante de orgãos
EP1680141B8 (de) 2003-11-04 2011-01-12 Novartis Vaccines and Diagnostics, Inc. Verfahren zur behandlung von soliden tumoren mit expression des cd40-zelloberflächen-antigens
EP1844815B1 (de) 2003-11-04 2011-09-14 Novartis Vaccines and Diagnostics, Inc. Kombinationstherapie von anti-CD20 und anti-CD40 Antikörpern zur Behandlung von B-Zell-bedingtem Krebs
CA2544951A1 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
NZ547157A (en) 2003-12-10 2009-07-31 Medarex Inc Interferon Alpha Antibodies and their uses
RS53984B1 (sr) 2003-12-10 2015-10-30 E. R. Squibb & Sons L.L.C. Ip-10 antitela i njihove upotrebe
WO2005058961A2 (en) * 2003-12-12 2005-06-30 Amgen Inc. Antibodies specific for human galanin, and uses thereof
SG10201404273QA (en) 2003-12-23 2014-10-30 Genentech Inc Novel anti-il 13 antibodies and uses thereof
SG166768A1 (en) 2003-12-23 2010-12-29 Rinat Neuroscience Corp Agonist anti-trkc antibodies and methods using same
MX350383B (es) 2004-01-09 2017-09-04 Pfizer Anticuerpos contra madcam.
LT2857418T (lt) 2004-02-06 2017-09-25 University Of Massachusetts Antikūnai prieš clostridium difficile toksinus ir jų panaudojimas
ES2567634T3 (es) 2004-02-09 2016-04-25 Human Genome Sciences, Inc. Proteínas de fusión de albúmina
US7807176B2 (en) 2004-03-19 2010-10-05 Genomidea, Inc. Polypeptide promoting vascular endothelial cell growth
US7973139B2 (en) 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
JP2008537873A (ja) 2004-03-31 2008-10-02 セントカー・インコーポレーテツド ヒトｇｌｐ−１ミメティボディ、組成物、方法および用途
JP5301152B2 (ja) 2004-04-07 2013-09-25 ライナット ニューロサイエンス コーポレイション 神経成長因子アンタゴニストを投与することによって骨癌の疼痛を処置するための方法
EP1755673B1 (de) 2004-04-12 2014-07-23 MedImmune, LLC Anti-il-9-antikörperformulierungen und deren verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
HUE035082T2 (en) 2004-06-21 2018-05-02 Squibb & Sons Llc Interferon alpha receptor 1 antibodies and their use
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
US6986264B1 (en) * 2004-07-15 2006-01-17 Carrier Corporation Economized dehumidification system
KR20070036130A (ko) 2004-07-16 2007-04-02 화이자 프로덕츠 인코포레이티드 항-아이지에프-1알 항체를 사용하는 비-혈액학적악성종양에 대한 조합 치료
BRPI0513959A (pt) 2004-07-30 2008-05-20 Rinat Neuroscience Corp anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
PL1781321T3 (pl) 2004-08-02 2014-07-31 Zenyth Operations Pty Ltd Sposób leczenia raka zawierający antagonistę VEGF-B
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
US20060121042A1 (en) 2004-10-27 2006-06-08 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
JP2008518629A (ja) 2004-11-08 2008-06-05 シェーリング コーポレイション Ｍｄｌ−１の腫瘍との関連およびその方法
KR101335798B1 (ko) 2005-02-15 2013-12-02 듀크 유니버시티 항-ｃｄ19 항체 및 종양학에서 이의 용도
EP1871806A2 (de) 2005-03-08 2008-01-02 Pharmacia & Upjohn Company LLC Antikörperzusammensetzungen gegen madcam
JP5153613B2 (ja) 2005-03-18 2013-02-27 メディミューン，エルエルシー 抗体のフレームワーク・シャッフル
EP2567976B1 (de) 2005-03-23 2017-07-19 Genmab A/S Antikörper gegen CD38 zur Behandling von multiplem Myelom
EP3058955B1 (de) 2005-03-24 2019-05-29 Millennium Pharmaceuticals, Inc. Ov064-bindende antikörper und verfahren zu deren verwendung
CA2603940A1 (en) * 2005-04-08 2006-10-19 Nancy Ulbrandt Antibodies against mammalian metapneumovirus
CN101203241B (zh) 2005-04-19 2012-02-22 西雅图基因公司 人源化抗-cd70结合物和其应用
NL1031674C2 (nl) 2005-04-25 2007-04-26 Pfizer Antilichamen tegen myostatine.
CA2763671A1 (en) 2005-04-26 2006-11-02 Pfizer Inc. P-cadherin antibodies
PE20061324A1 (es) 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
CA2607281C (en) 2005-05-05 2023-10-03 Duke University Anti-cd19 antibody therapy for autoimmune disease
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
WO2006125117A2 (en) 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
PE20061444A1 (es) 2005-05-19 2007-01-15 Centocor Inc Anticuerpo anti-mcp-1, composiciones, metodos y usos
EP1893647A2 (de) 2005-06-23 2008-03-05 MedImmune, Inc. Antikörperformulierungen mit optimierten aggregations- und fragmentierungsprofilen
AU2006265002B2 (en) 2005-06-30 2012-09-20 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
JP5171621B2 (ja) 2005-07-07 2013-03-27 シアトル ジェネティックス， インコーポレイテッド フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物
US7482124B2 (en) * 2005-07-08 2009-01-27 Bristol-Myers Squibb Company Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
CA2615460A1 (en) 2005-08-08 2007-02-15 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
US20070202512A1 (en) * 2005-08-19 2007-08-30 Bristol-Myers Squibb Company Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
CA2621371C (en) 2005-09-07 2018-05-15 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
EP1762575A1 (de) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identifizierung Tumor-assoziierter Antigene für Diagnoseund Therapie
CA2623236A1 (en) 2005-09-26 2007-04-05 Medarex, Inc. Human monoclonal antibodies to cd70
KR20080080109A (ko) 2005-11-04 2008-09-02 바이오겐 아이덱 엠에이 인코포레이티드 도파민성 뉴런의 신경돌기 성장 및 생존의 촉진 방법
EP3299027A1 (de) 2005-11-04 2018-03-28 Genentech, Inc. Verwendung von komplementweginhibitoren zur behandlung von augenkrankheiten
MY153249A (en) 2005-11-14 2015-01-29 Rinat Neuroscience Corp Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
EP1790664A1 (de) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
AU2006340750B2 (en) 2005-11-28 2013-03-07 Zymogenetics, Inc. IL-21 antagonists
CA2631181A1 (en) 2005-12-02 2007-06-07 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
WO2007064911A1 (en) * 2005-12-02 2007-06-07 Biogen Idec Inc. Anti-mouse cd20 antibodies and uses thereof
EP1954311A4 (de) 2005-12-07 2009-12-23 Medarex Inc Ctla-4-antikörper-dosierungseskalationstherapien
US8383118B2 (en) 2005-12-08 2013-02-26 Medarex, Inc. Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1
EP2336181A1 (de) 2005-12-09 2011-06-22 UCB Pharma, S.A. Antikörpermoleküle mit menschlicher IL-6-Spezifizität
UA99097C2 (ru) 2005-12-12 2012-07-25 Ф. Хоффманн-Ля Рош Аг Композиция, содержащая антитела к амилоиду бета 4, имеющие гликозилированный вариабельный участок
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
SI1971366T1 (sl) 2005-12-29 2014-10-30 Janssen Biotech, Inc. Humana protitelesa anti-il-23, sestavki, postopki in uporabe
CA2913655A1 (en) 2006-01-27 2007-08-09 Biogen Ma Inc. Nogo receptor antagonists
EP2650306A1 (de) 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
WO2007115148A2 (en) * 2006-03-31 2007-10-11 Centocor, Inc. Human mimetic epo hinge core mimetibodies
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
KR20090029184A (ko) 2006-04-07 2009-03-20 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 항체 조성물 및 신생물성 질병의 치료 방법
MX2008013508A (es) 2006-04-21 2008-10-31 Novartis Ag Composiciones farmaceuticas de anticuerpos antagonistas anti-cd40.
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
KR101496433B1 (ko) 2006-06-07 2015-02-26 바이오얼라이언스 씨.브이. 암세포 상에서 발현되는 ｃｄ-43 및 ｃｅａ 상의 에피토프를 함유하는 탄수화물을 인식하는 항체 및 이를 이용하는 방법
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US20080112888A1 (en) 2006-06-30 2008-05-15 Schering Corporation Igfbp2 biomarker
EP2054444B1 (de) 2006-08-04 2016-11-02 MedImmune Limited Antikörper gegen erbb2
JP5256199B2 (ja) 2006-08-07 2013-08-07 テヴァ バイオファーマシューティカルズ ユーエスエー，インコーポレーティッド アルブミン−インスリン融合タンパク質
TW200817437A (en) 2006-08-11 2008-04-16 Medarex Inc Monoclonal antibodies against stromal cell derived factor-1 (SDF-1)
EP2526959B1 (de) 2006-08-11 2017-08-02 CSL Limited Behandlung von lungenerkrankungszuständen
ES2439994T3 (es) 2006-08-28 2014-01-27 Kyowa Hakko Kirin Co., Ltd. Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano
MX2009002418A (es) 2006-09-05 2009-04-23 Medarex Inc Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
EP3569245A1 (de) 2006-09-26 2019-11-20 Genmab A/S Kombinationsbehandlung von cd38-exprimierenden tumoren
KR101722261B1 (ko) 2006-10-02 2017-04-03 메다렉스, 엘.엘.시. Ｃｘｃｒ4에 결합하는 인간 항체 및 이의 용도
AU2007313300A1 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
CN101588816B (zh) 2006-10-19 2013-06-19 Csl有限公司 白介素-13受体α1的高亲和性抗体拮抗物
WO2008060814A2 (en) 2006-10-19 2008-05-22 Merck & Co., Inc. ANTI-IL-13Rα1 ANTIBODIES AND THEIR USES THEREOF
KR20090088891A (ko) 2006-11-15 2009-08-20 메다렉스, 인코포레이티드 비티엘에이에 대한 인간 단일클론 항체 및 이용 방법
KR101552735B1 (ko) 2006-12-01 2015-09-14 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
WO2008070593A2 (en) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
EP2687232A1 (de) 2006-12-06 2014-01-22 MedImmune, LLC Verfahren zur Behandlung von systemischem Lupus erythematodes
CA2672828A1 (en) 2006-12-13 2008-06-26 Schering Corporation Methods of treatment
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
KR20090088946A (ko) 2006-12-14 2009-08-20 메다렉스, 인코포레이티드 씨디70에 결합하는 인간 항체 및 이의 용도
JP5386364B2 (ja) 2006-12-18 2014-01-15 ジェネンテック， インコーポレイテッド 抗Ｎｏｔｃｈ３アンタゴニスト抗体とＮｏｔｃｈ３関連疾患の予防及び治療におけるその使用
TW200843794A (en) * 2006-12-21 2008-11-16 Centocor Inc Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
KR20120017469A (ko) 2007-01-05 2012-02-28 유니버시티 오브 취리히 질환 특이적 결합 분자 및 표적을 제공하는 방법
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
CN101636168B (zh) 2007-01-09 2013-05-29 比奥根艾迪克Ma公司 Sp35抗体及其用途
SG178744A1 (en) 2007-02-02 2012-03-29 Biogen Idec Inc Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
WO2008101184A2 (en) * 2007-02-16 2008-08-21 The Board Of Trustees Of Southern Illinois University Arl-1 specific antibodies
US8685666B2 (en) * 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
BRPI0807952A2 (pt) 2007-02-20 2014-06-10 Anaptysbio Inc Sistemas de hipermutação somática
JP5642972B2 (ja) 2007-02-21 2014-12-17 ユニバーシティー オブ マサチューセッツＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ Ｃ型肝炎ウイルス（ｈｃｖ）に対するヒト抗体およびその使用
JP5357782B2 (ja) 2007-02-21 2013-12-04 バクシネックス インコーポレーティッド 抗原負荷ＣＤ１ｄ分子によるＮＫＴ細胞活性の調節
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
EP2447719B1 (de) 2007-02-26 2016-08-24 Oxford BioTherapeutics Ltd Proteine
EP1970384A1 (de) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
CA2682292A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
US7807168B2 (en) * 2007-04-10 2010-10-05 Vaccinex, Inc. Selection of human TNFα specific antibodies
US20100196328A1 (en) * 2007-04-25 2010-08-05 Tonya Bliss ISCHEMIA-INDUCED NEOVASCULARIZATION IS ENHANCED BY hCNS-SC TRANSPLANTATION
TWI570135B (zh) 2007-04-27 2017-02-11 建南德克公司 高效、穩定且非免疫抑制之抗－ｃｄ４抗體
EP2068925A4 (de) 2007-05-07 2011-08-31 Medimmune Llc Anti-icos-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen
HUE036885T2 (hu) 2007-05-14 2018-08-28 Astrazeneca Ab Eljárás a bazofil-szint csökkentésére
EP1997832A1 (de) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
WO2009097006A2 (en) 2007-08-10 2009-08-06 Medarex, Inc. Hco32 and hco27 and related examples
CN111909273B (zh) * 2007-08-29 2024-03-26 塞诺菲-安万特股份有限公司 人源化的抗-cxcr5抗体、其衍生物及它们的应用
WO2009026660A1 (en) 2007-08-30 2009-03-05 Walter And Eliza Hall Institute Of Medical Research Dendritic cell marker and uses thereof
WO2009032845A2 (en) 2007-09-04 2009-03-12 Compugen, Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP2203747B1 (de) 2007-09-28 2016-11-30 Welcome Receptor Antibodies PTY LTD Anti-Calcitonin-Antikörper
WO2009048605A1 (en) * 2007-10-11 2009-04-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
EP2050764A1 (de) 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
JP5330398B2 (ja) 2007-10-26 2013-10-30 シーエスエル、リミテッド サイトカインムテイン
KR20100091170A (ko) 2007-11-02 2010-08-18 노파르티스 아게 저밀도-지단백질 수용체-관련 단백질 ６ (ｌｒｐ６)을 조정하기 위한 분자 및 방법
PT2219452E (pt) 2007-11-05 2016-01-26 Medimmune Llc Métodos de tratamento de esclerodermia
NZ599777A (en) 2007-11-07 2013-09-27 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
EP2217625B1 (de) 2007-11-08 2021-08-04 Precision Biologics, Inc. Rekombinante monoklonale antikörper und entsprechende antigene für kolon- und pankreaskarzinom
CA2702630C (en) * 2007-11-08 2017-11-21 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
PT3002298T (pt) 2007-11-21 2019-11-20 Univ Oregon Health & Science Anticorpos monoclonais anti-fator xi e métodos de utilização dos mesmos
WO2015164330A1 (en) 2014-04-21 2015-10-29 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
EP3103813A1 (de) 2007-12-07 2016-12-14 ZymoGenetics, Inc. Anti-humane il-21 monoklonale antikörper
KR101615935B1 (ko) 2007-12-14 2016-04-28 노보 노르디스크 에이/에스 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도
RU2570559C2 (ru) 2007-12-17 2015-12-10 Пфайзер Лимитед Лечение интерстициального цистита
KR101672271B1 (ko) 2007-12-18 2016-11-03 바이오얼라이언스 씨.브이. 암세포에서 발현된 ｃｄ-43 및 ｃｅａ 상의 탄수화물 함유 에피토프를 인식하는 항체 및 그것의 사용 방법
CA2711499C (en) 2008-01-10 2018-09-25 Research Development Foundation Vaccines and diagnostics for the ehrlichioses
JP2011509675A (ja) 2008-01-18 2011-03-31 メディミューン，エルエルシー 部位特異的コンジュゲーションのためのシステイン操作抗体
AU2009207645B2 (en) 2008-01-25 2014-11-13 Aarhus Universitet Selective exosite inhibition of PAPP-A activity against IGFBP-4
NZ587440A (en) 2008-02-05 2013-01-25 Pfizer Antibodies specific for human integrin alpha 5 - beta 1 and their uses for treating tumours
HRP20160855T1 (hr) 2008-02-08 2016-09-23 Medimmune, Llc Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda
JP5697027B2 (ja) 2008-02-15 2015-04-08 タフツ ユニバーシティー マウス網膜上への細胞膜傷害複合体（ｍａｃ）生成のヒト化モデル、並びに、黄斑変性の処置のための組成物とキットと方法
WO2009120922A2 (en) 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions and methods for inhibiting pdgfrbeta and vegf-a
US20090269786A1 (en) * 2008-04-25 2009-10-29 The Board Of Trustees Of The University Of Illinois RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies
US8163551B2 (en) 2008-05-02 2012-04-24 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
JP2011526892A (ja) 2008-06-30 2011-10-20 アンジオブラスト システムズ，インコーポレーテッド 併用療法を使用した眼疾患及び過剰血管新生の治療
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MY153074A (en) 2008-08-14 2014-12-31 Teva Pharmaceuticals Australia Pty Ltd Anti-il-12/11-23 antibodies
JP5611210B2 (ja) 2008-09-07 2014-10-22 グリコネックス インコーポレイテッド 抗拡張ｉ型スフィンゴ糖脂質抗体、その誘導体および使用
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
EP2166021A1 (de) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
BRPI0919881B1 (pt) 2008-10-31 2021-09-08 Centocor Ortho Biotech Inc Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
WO2010067308A2 (en) 2008-12-08 2010-06-17 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
AU2009328505B2 (en) 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
US8349325B2 (en) 2008-12-23 2013-01-08 Abbott Laboratories Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
US20100158878A1 (en) * 2008-12-23 2010-06-24 Alexandra Capela Target populations of oligodendrocyte precursor cells and methods of making and using same
JP2012514458A (ja) 2008-12-31 2012-06-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗リンホトキシン抗体
MX2011007647A (es) 2009-01-21 2011-09-01 Amgen Inc Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
CA2750581A1 (en) 2009-01-21 2010-07-29 Oxford Biotherapeutics Ltd. Pta089 protein
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
BRPI1008532B1 (pt) 2009-02-12 2021-12-14 Janssen Biotech, Inc Arcabouço de proteína isolada, método para construção de uma biblioteca de arcabouço de proteína isolada, molécula de ácido nucleico isolada, vetor de ácido nucleico isolado, célula hospedeira de bactéria ou fungo, composição, dispositivo médico e artigo de manufatura para uso farmacêutico ou de diagnóstico em seres humanos
WO2010093993A2 (en) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
LT2398902T (lt) 2009-02-20 2023-12-27 Astellas Pharma Inc. Vėžio diagnostikos ir gydymo būdai bei kompozicijos
US8420084B2 (en) 2009-03-05 2013-04-16 Medarex, Inc. Fully human antibodies specific to CADM1
EP2411412B1 (de) 2009-03-24 2015-05-27 Teva Biopharmaceuticals USA, Inc. Humanisierte antikörper gegen licht und anwendungen davon
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
CN102482639B (zh) 2009-04-03 2016-01-06 医学研究会 活化诱导胞苷脱氨酶(aid)突变体及使用方法
DK2421898T3 (en) 2009-04-20 2016-05-30 Oxford Biotherapeutics Ltd Cadherin-17 SPECIFIC ANTIBODIES
US9062116B2 (en) 2009-04-23 2015-06-23 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
EP2421981B1 (de) * 2009-04-23 2013-08-14 Neurotech USA, Inc. Zelllinien zur produktion von prostaglandin-f2-alpha (pgf2a) und verwendungen davon
EP2424894A1 (de) 2009-04-27 2012-03-07 Novartis AG Zusammensetzungen und verfahhren zur anwendung von für die beta1-untereinheit des il-12-rezeptors spezifischen antikörpern
JP5766179B2 (ja) 2009-04-27 2015-08-19 ノバルティス アーゲー 筋肉増殖を増加させるための組成物および方法
SG175436A1 (en) 2009-05-04 2011-12-29 Abbott Res Bv Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
ES2647823T3 (es) 2009-05-08 2017-12-26 Vaccinex, Inc. Anticuerpos anti-CD100 y métodos de uso de los mismos
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
JP6059985B2 (ja) 2009-06-18 2017-01-11 ファイザー・インク 抗ｎｏｔｃｈ−１抗体
AU2010270979B2 (en) 2009-06-22 2015-04-23 Medimmune, Llc Engineered Fc regions for site-specific conjugation
SMT201700293T1 (it) 2009-07-20 2017-07-18 Bristol Myers Squibb Co Combinazione di un anticorpo anti-ctla-4 con etoposide per il trattamento sinergico di malattie proliferative
CN102762593B (zh) 2009-07-31 2015-05-20 梅达雷克斯有限责任公司 抗btla的完全人抗体
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
ES2699718T3 (es) 2009-09-15 2019-02-12 Medlmmune Ltd Células para expresión transitoria y usos de las mismas
PL2477656T3 (pl) 2009-09-15 2017-09-29 Csl Limited Leczenie stanów neurologicznych
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
CA2777226A1 (en) 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
EP2470569A1 (de) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antikörper gegen epha10
MY173390A (en) 2009-10-23 2020-01-22 Takeda Pharmaceuticals Co Anti-gcc antibody molecules and related compositions and methods
US20120282177A1 (en) 2009-11-02 2012-11-08 Christian Rohlff ROR1 as Therapeutic and Diagnostic Target
EP2496243A2 (de) 2009-11-04 2012-09-12 Erasmus University Medical Center Rotterdam Neuartige verbindungen zur modulierung der gefässneubildung und behandlungsverfahren mit diesen verbindungen
EP2322555A1 (de) 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antikörper spezifisch für Claudin 6 (CLDN6)
NZ716587A (en) 2009-11-11 2017-10-27 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
EP2325322A1 (de) 2009-11-23 2011-05-25 4-Antibody AG Retrovirusvektorpartikel und Verfahren zu deren Erzeugung und Verwendung
WO2011067711A2 (en) 2009-12-01 2011-06-09 Compugen Ltd Novel heparanase splice variant
AR080291A1 (es) 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
SG183867A1 (en) 2010-03-11 2012-10-30 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
PE20130203A1 (es) 2010-03-17 2013-03-24 Abbott Res Bv Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
US20110229921A1 (en) * 2010-03-18 2011-09-22 Abbott Laboratories METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS
EP2371864A1 (de) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
HUE036157T2 (hu) 2010-03-30 2018-06-28 Janssen Biotech Inc Humanizált IL-25 ellenanyagok
EP3165540A1 (de) 2010-04-13 2017-05-10 Celldex Therapeutics, Inc. Antikörper zur bindung von humanem cd27 und verwendungen davon
SMT202000306T1 (it) 2010-04-16 2020-07-08 Biogen Ma Inc Anticorpi anti-vla-4
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
JP6055404B2 (ja) 2010-06-15 2016-12-27 ゲンマブ エー／エス 組織因子に対するヒト抗体薬物結合体
WO2011163558A1 (en) 2010-06-25 2011-12-29 Abbott Laboratories Materials and methods for assay of anti-hepatitis c virus (hcv) antibodies
EP2404936A1 (de) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Krebstherapie mittels CLDN6-zielgerichteter Antikörper im lebenden Organismus
EP2598126A2 (de) 2010-07-30 2013-06-05 Saint Louis University Verfahren zur behandlung von schmerz
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
CA2843684A1 (en) 2010-08-13 2012-02-16 Tufts University Compositions, kits and methods for treatment of macular degeneration using soluble membrane-independent cd59 protein
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
CA2809369A1 (en) 2010-08-27 2012-03-01 Stem Centrx, Inc. Notum protein modulators and methods of use
AU2011295902B2 (en) 2010-09-02 2014-12-04 Vaccinex, Inc. Anti-CXCL13 antibodies and methods of using the same
CA2810016A1 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
PT2614082T (pt) 2010-09-09 2018-12-03 Pfizer Moléculas de ligação a 4-1bb
EP2616100B1 (de) 2010-09-17 2016-08-31 Compugen Ltd. Zusammensetzungen und verfahren zur behandlung von wirkstoffresistentem multiplem myelom
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
EP2625203A1 (de) 2010-10-05 2013-08-14 Novartis AG Anti-il12rbeta1-antikörper und ihre verwendung zur behanldung von autoimmun- und entzündungserkrankungen
BR112013008765B8 (pt) 2010-10-11 2023-05-02 Biogen Idec Int Neuroscience Gmbh Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
US20120115244A1 (en) 2010-11-09 2012-05-10 Abbott Laboratories Materials and methods for immunoassay of pterins
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012118547A1 (en) 2010-12-08 2012-09-07 Stem Centrx, Inc. Novel modulators and methods of use
SG191039A1 (en) 2010-12-15 2013-08-30 Wyeth Llc Anti-notch1 antibodies
US9283271B2 (en) 2010-12-17 2016-03-15 Neurimmune Holding Ag Human anti-SOD1 antibodies
US9428567B2 (en) 2010-12-22 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University Antagonists of interleukin-2 receptor
US9683054B2 (en) 2010-12-31 2017-06-20 BioAlta, LLC Express humanization of antibodies
CN103620405B (zh) 2010-12-31 2016-05-25 生物蛋白有限公司 全面单克隆抗体产生
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
AU2012222833B2 (en) 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
US20130344074A1 (en) 2011-03-16 2013-12-26 Sanofi Uses of a dual v region antibody-like protein
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
BR112013026199A2 (pt) 2011-04-15 2017-11-07 Compugen Ltd polipeptídeo isolado, proteína de fusão, sequência de ácidos nucleicos, vetor de expressão ou um vírus, célula recombinante, método de produção de um polipeptídeo com ectodomínio solúvel lsr, ou seu fragmento ou proteína de fusão, composição farmacêutica, uso de um anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, uso do anticorpo ou do fragmento de ligação ao antígeno, uso de qualquer um de um polipeptídeo isolado, método de regulação por cima de citocinas, indução da expansão de células t, promoção da imunidade de células t específica antigênica e promoção da ativação das células t cd4+ e/ou cd8+ em um sujeito, método para potenciação de uma resposta imune secundária a um antígeno em um paciente, método de uso de pelo menos um de: um polipeptídeo isolado, método para tratamento ou prevenção de uma condição relacionada com o sistema imune, método para tratamento ou prevenção de uma doença infecciosa, método para diagnóstico de uma doença em um sujeito, método de produção de um polipeptídeo com ectodomínio solúvel tmem25, vsig10, ly6g6f, ou seu fragmento ou proteína de fusão, anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, método de imunoterapia em um paciente e método para combinação de vacinação terapêutica com um antígeno em conjunto com a administração de qualquer um de um polipeptídeo
DK2699598T3 (en) 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
DK3311834T3 (da) 2011-05-02 2026-04-20 Millennium Pharmaceuticals Inc Formulering til anti-alfa4beta7-antistof
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
US9321842B2 (en) 2011-05-13 2016-04-26 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer
EP2714738B1 (de) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalente und monovalente multispezifische komplexe und ihre verwendungen
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
BR112013031485B1 (pt) 2011-06-10 2022-06-14 Medimmune, Llc Anticorpo monoclonal isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, usos e método in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais
MX358447B (es) 2011-06-13 2018-08-21 Abgenomics Cooeperatief U A Star Anticuerpos anti-psgl-1 y usos de los mismos.
HUE041391T2 (hu) 2011-06-23 2019-05-28 Biogen Int Neuroscience Gmbh Anti-alfa-szinukleinkötõ molekulák
RS55716B1 (sr) 2011-06-28 2017-07-31 Oxford Biotherapeutics Ltd Terapeutski i dijagnostički cilj
UA114478C2 (uk) 2011-06-28 2017-06-26 Берлін-Хемі Аг Антитіло, яке специфічно зв'язується з bst1
MX358726B (es) 2011-06-29 2018-09-03 Amgen Inc Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales.
WO2013001517A1 (en) 2011-06-30 2013-01-03 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
HUE040276T2 (hu) 2011-07-01 2019-02-28 Novartis Ag Eljárás metabolikus rendellenességek kezelésére
AP2014007415A0 (en) 2011-07-11 2014-02-28 Glenmark Pharmaceuticals Sa Antibodies that bind to OX40 and their uses
BR112014003315A2 (pt) 2011-08-15 2017-03-01 Univ Chicago composições e métodos relacionados a anticorpos para a proteína a estafilocócica
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
ES2908046T3 (es) 2011-09-09 2022-04-27 Medimmune Ltd Anticuerpos anti-siglec-15 y usos de los mismos.
ES2925654T3 (es) 2011-09-30 2022-10-19 Dana Farber Cancer Inst Inc Péptidos terapéuticos que comprenden anticuerpos que se unen a la secuencia A relacionada con el polipéptido del CMH de clase I (MICA)
AR087973A1 (es) 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos
US9316645B2 (en) 2011-10-07 2016-04-19 Brown University Methods, compositions and kits for imaging cells and tissues using nanoparticles and spatial frequency heterodyne imaging
AU2012332588B2 (en) 2011-11-01 2017-09-07 Bionomics, Inc. Methods of blocking cancer stem cell growth
WO2013067054A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Antibodies and methods of treating cancer
EP2773664A1 (de) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49-antikörper
US9221907B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Anti-GPR49 monoclonal antibodies
CA2854233C (en) 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
BR112014011028B1 (pt) 2011-11-07 2021-03-02 Medimmune, Llc anticorpo biespecífico, composição, e, uso da composição
RU2014114015A (ru) 2011-11-08 2015-12-20 Пфайзер Инк. Способы лечения воспалительных расстройств с использованием антител против m-csf
AU2012335205A1 (en) 2011-11-11 2014-05-29 Rinat Neuroscience Corp. Antibodies specific for Trop-2 and their uses
EP2783219A1 (de) 2011-11-21 2014-10-01 Bristol-Myers Squibb Company Verfahren zur bestimmung der empfindlichkeit eines virus gegenüber einem bindungsinhibitor
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
HK1204328A1 (en) 2011-12-22 2015-11-13 瑞纳神经科学公司 Human growth hormone receptor antagonist antibodies and methods of use thereof
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
US8993248B2 (en) 2011-12-31 2015-03-31 Abbott Laboratories Truncated human vitamin D binding protein and mutation and fusion thereof and related materials and methods of use
KR20140126357A (ko) 2012-02-01 2014-10-30 컴퓨젠 엘티디. C1orf32 항체 및 이의 암 치료를 위한 용도
EP3575794A1 (de) 2012-02-10 2019-12-04 Seattle Genetics, Inc. Detektion und behandlung von cd30+karzinomen
PE20190658A1 (es) 2012-02-24 2019-05-08 Abbvie Stemcentrx Llc Moduladores y metodos de empleo novedosos
JP2015513406A (ja) 2012-03-12 2015-05-14 ハンファ ケミカル コーポレーション 改変グルタミン合成酵素をコードするポリヌクレオチドを含む発現ベクターおよびこれを用いた標的タンパク質の製造方法
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
EA033110B1 (ru) 2012-04-11 2019-08-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
EP2841101B1 (de) 2012-04-26 2019-08-07 University Of Chicago Zusammensetzungen und verfahren in zusammenhang mit antikörpern zur neutralisierung der koagulaseaktivität bei einer staphylococcus-aureus-erkrankung
WO2013161958A1 (ja) 2012-04-27 2013-10-31 日本ケミカルリサーチ株式会社 新規な発現ベクター
PT2662386T (pt) 2012-05-07 2019-06-14 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Anticorpos que se ligam a plac1 e bloqueiam a interação entre plac1 e fgf7
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013166594A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
CN104470541A (zh) 2012-05-14 2015-03-25 比奥根艾迪克Ma公司 用于治疗涉及运动神经元的疾患的lingo-2拮抗剂
WO2013174403A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
SI2852408T1 (sl) 2012-05-23 2017-10-30 Ganymed Pharmaceuticals Gmbh Kombinacijska terapija, ki vključuje protitelesa proti claudin 18.2 za zdravljenje raka
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
DK3725810T3 (da) 2012-05-23 2022-07-25 Astellas Pharma Inc Kombinationterapi, der involverer antistoffer mod claudin 18.2 til behandling af cancer
AP2014008145A0 (en) 2012-06-08 2014-12-31 Glenmark Pharmaceuticals Sa Humanized anti-trkA antibodies with animo acid substitutions
CA2871656A1 (en) 2012-06-11 2013-12-19 Eli Lilly And Company Fibroblast growth factor 21 variants
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
EP2674495A1 (de) 2012-06-14 2013-12-18 Sanofi CHO-Expressionssystem
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN104768571B (zh) 2012-07-13 2018-11-09 酵活有限公司 多价异多聚体支架设计和构建体
CN116574185A (zh) 2012-07-25 2023-08-11 塞尔德克斯医疗公司 抗kit抗体及其用途
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
TW201420606A (zh) 2012-08-22 2014-06-01 Lilly Co Eli 同源二聚體蛋白
JP2015534564A (ja) 2012-10-09 2015-12-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 脱髄障害の治療のための併用療法および使用
EP2906683B1 (de) 2012-10-15 2017-05-31 Bristol-Myers Squibb Company Säugerzellkulturverfahren zur proteinproduktion
HK1216428A1 (zh) 2012-11-09 2016-11-11 辉瑞公司 血小板衍生生长因子b之特异性抗体及其组合物和用途
WO2014075788A1 (en) 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2014075697A1 (en) 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
EP3766903A3 (de) 2012-11-13 2021-02-17 BioNTech SE Bispezifischer antikörper anti claudin xcd3 zur behandlung von krebserkrankungen mit claudin-expression
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
JP6396313B2 (ja) 2012-12-07 2018-09-26 ファイザー・インク 操作された単量体抗体断片
ES2914814T3 (es) 2012-12-17 2022-06-16 Pf Argentum Ip Holdings Llc Tratamiento de células enfermas CD47+ con fusiones SIRP Alfa-Fc
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
PT2935326T (pt) 2012-12-21 2020-09-14 Biogen Ma Inc Anticorpos anti-tau humanos
EP2938631B1 (de) 2012-12-31 2018-12-19 Neurimmune Holding AG Rekombinante menschliche antikörper zur therapie und vorbeugung von erkrankungen im zusammenhang mit polyomavirus
EA201591153A1 (ru) 2013-01-02 2016-01-29 Гленмарк Фармасьютикалс С.А. Антитела, связывающиеся с tl1a, и их применение
LT2953969T (lt) 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
EP2956169B1 (de) 2013-02-12 2018-04-11 THE UNITED STATES OF AMERICA, represented by the S Monoklonale antikörper zur neutralisierung von noroviren
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
WO2014129895A1 (en) 2013-02-19 2014-08-28 Stichting Vu-Vumc Means and method for increasing the sensitivity of cancers for radiotherapy
HRP20221319T1 (hr) 2013-02-20 2022-12-23 Astellas Pharma Inc. Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
BR112015019909A2 (pt) 2013-02-22 2017-08-29 Abbvie Stemcentrx Llc Conjugados anticorpo-fármaco, composição farmacêutica, usos dos mesmos, e kit
WO2014149699A1 (en) 2013-03-15 2014-09-25 Eli Lilly And Company Bifunctional protein
KR20150130462A (ko) 2013-03-15 2015-11-23 다나-파버 캔서 인스티튜트 인크. 치료 펩티드
US10119134B2 (en) 2013-03-15 2018-11-06 Abvitro Llc Single cell bar-coding for antibody discovery
WO2014152232A2 (en) 2013-03-15 2014-09-25 Dyax Corp. Anti-plasma kallikrein antibodies
WO2014144666A2 (en) 2013-03-15 2014-09-18 The University Of Chicago Methods and compositions related to t-cell activity
HRP20200019T1 (hr) 2013-03-18 2020-04-03 Astellas Pharma Inc. Terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
EP2981821B2 (de) 2013-04-02 2021-11-03 Merck Sharp & Dohme Corp. Immunhistochemischer test zum nachweis der expression des liganden 1 für programmierten zelltod (pd-l1) in tumorgewebe
EP2983710B1 (de) 2013-04-09 2019-07-31 Annexon, Inc. Behandlungsverfahren für neuromyelitis optica
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
MX2015015339A (es) 2013-05-07 2016-07-15 Rinat Neuroscience Corp Anticuerpos de receptor anti-glucagon y metodos de uso de los mismos.
WO2014182970A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
EP3583950A1 (de) 2013-05-09 2019-12-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Single-domain-vhh-antikörper gegen norovirus gi.1 und gii.4 und deren verwendung
EP2996721B1 (de) 2013-05-13 2021-10-06 Tufts University Zusammensetzungen zur behandlung von adam8-exprimierendem krebs
WO2014186878A1 (en) 2013-05-24 2014-11-27 Cashman Neil R Cell senescence markers as diagnostic and therapeutic targets
SG11201509982UA (de) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
WO2014200349A1 (en) 2013-06-13 2014-12-18 Fast Forward Pharmaceutical B.V. Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
CA2916694C (en) 2013-06-28 2023-01-17 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
WO2015006507A1 (en) 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
EP3747465A1 (de) 2013-07-31 2020-12-09 BioNTech AG Diagnose und therapie von krebs mit krebsstammzellen
PE20160671A1 (es) 2013-08-02 2016-07-09 Pfizer Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco
KR20160042987A (ko) 2013-08-14 2016-04-20 노파르티스 아게 산발성 봉입체 근염을 치료하는 방법
KR102313341B1 (ko) 2013-08-26 2021-10-18 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
AU2014312215B2 (en) 2013-08-28 2020-02-27 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
AU2014312310A1 (en) 2013-08-28 2016-04-07 Abbvie Stemcentrx Llc Novel SEZ6 modulators and methods of use
CN105722860A (zh) 2013-09-24 2016-06-29 梅迪塞纳医疗股份有限公司 白介素-2融合蛋白及其应用
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
EP3733244A1 (de) 2013-10-02 2020-11-04 Medlmmune, LLC Neutralisierende antiinflueanza-a-virus-antikörper und verwendungen davon
EP2868328A1 (de) 2013-10-31 2015-05-06 Universitätsklinikum Regensburg Blockade Il-3 bei systemischem Lupus erythematosus und multipler Sklerose
MX388027B (es) 2013-11-13 2025-03-19 Pfizer Anticuerpos específicos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos.
EA201691078A1 (ru) 2013-12-06 2017-01-30 Дана-Фарбер Кэнсер Инститьют, Инк. Терапевтические пептиды
KR102311761B1 (ko) 2013-12-09 2021-10-13 알라코스 인크. 항-Siglec-8 항체 및 그의 사용 방법
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
JP6701079B2 (ja) 2013-12-20 2020-05-27 インターベット インターナショナル ベー． フェー． ヒトｐｄ−１に対するイヌ化マウス抗体
SG11201605580RA (en) 2014-01-10 2016-10-28 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33)
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
AU2015209481C1 (en) 2014-01-21 2020-10-29 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
EP2910645A1 (de) 2014-02-25 2015-08-26 STRATIFYER Molecular Pathology GmbH Verfahren und Zusammensetzungen zur Vorhersage der therapeutischen Wirksamkeit von Krebsbehandlungen und Krebsprognose bei Antikörperbehandlung
CA2939931C (en) 2014-02-28 2025-04-22 Allakos Inc. METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SIGLEC8
WO2015139020A2 (en) 2014-03-14 2015-09-17 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers
PE20161439A1 (es) 2014-03-21 2017-01-26 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
IL295414B2 (en) 2014-03-27 2026-02-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
CA2944649C (en) 2014-04-04 2022-06-21 Bionomics, Inc. Humanized antibodies that bind lgr5
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
US9777070B2 (en) 2014-04-30 2017-10-03 Pfizer Inc Anti-PTK7 antibody-drug conjugates
ES2936810T3 (es) 2014-05-16 2023-03-22 Pfizer Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería
EP3142700B1 (de) 2014-05-16 2021-03-03 Medimmune, LLC Moleküle mit veränderter neonater fc-rezeptorbindung mit verbesserten therapeutischen und diagnostischen eigenschaften
SG10201912986PA (en) 2014-05-28 2020-02-27 Agenus Inc Anti-gitr antibodies and methods of use thereof
MX383150B (es) 2014-06-02 2025-03-13 Us Health Receptores quiméricos de antígeno que tienen como diana a cd-19.
DK3154583T3 (da) 2014-06-04 2021-03-22 Biontech Res And Development Inc Humane monoklonale antistoffer mod gangliosid gd2
PT3151921T (pt) 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
US20170291939A1 (en) 2014-06-25 2017-10-12 Novartis Ag Antibodies specific for il-17a fused to hyaluronan binding peptide tags
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN106661600B (zh) 2014-07-16 2021-04-06 唐恩生物科技股份有限公司 用于扩增核酸样品的等温方法
EP4406549A3 (de) 2014-07-29 2025-01-08 Neurimmune Holding AG Vom menschen abgeleitete anti-huntingtin-(htt)-antikörper und verwendungen davon
EP3177322A4 (de) 2014-08-08 2018-07-18 Alector LLC Anti-trem2-antikörper und verfahren zur verwendung davon
WO2016025523A1 (en) 2014-08-11 2016-02-18 Shire Human Genetic Therapies, Inc. Lysosomal targeting and uses thereof
AU2015305754B2 (en) 2014-08-19 2018-10-25 Merck Sharp & Dohme Llc Anti-tigit antibodies
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
ES2895750T3 (es) 2014-09-15 2022-02-22 Abvitro Llc Secuenciación de alto rendimiento de colecciones de nucleótidos
US10450376B2 (en) 2014-09-16 2019-10-22 Symphogen A/S Anti-MET antibodies and compositions
KR20230104759A (ko) 2014-09-30 2023-07-10 뉴리뮨 홀딩 아게 인간-유래의 항-디펩티드 반복체(dpr) 항체
SG11201702606TA (en) 2014-10-03 2017-04-27 Massachusetts Inst Technology Antibodies that bind ebola glycoprotein and uses thereof
WO2016070001A1 (en) 2014-10-31 2016-05-06 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind b7-h4
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
US11559801B2 (en) 2014-11-03 2023-01-24 Tangen Biosciences, Inc. Apparatus and method for cell, spore, or virus capture and disruption
HUE070383T2 (hu) 2014-11-05 2025-06-28 Annexon Inc Humanizált C1Q anti-komplement faktor antitestek és alkalmazásaik
MY189836A (en) 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
MA41022A (fr) 2014-11-24 2017-10-03 Shire Human Genetic Therapies Ciblage lysosomial et utilisations correspondantes
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
US10072070B2 (en) 2014-12-05 2018-09-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Potent anti-influenza A neuraminidase subtype N1 antibody
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
PL3333191T3 (pl) 2014-12-11 2021-05-04 Pierre Fabre Médicament Przeciwciała przeciwko c10orf54 i ich zastosowania
CN113563468A (zh) 2014-12-19 2021-10-29 雷根尼桑斯公司 结合人c6的抗体及其用途
JP7211703B2 (ja) 2014-12-22 2023-01-24 ザ ロックフェラー ユニバーシティー 抗ｍｅｒｔｋアゴニスト抗体及びその使用
CN107207594B (zh) 2014-12-23 2019-05-07 百时美施贵宝公司 针对tigit的抗体
DK3240801T3 (da) 2014-12-31 2021-02-08 Checkmate Pharmaceuticals Inc Kombinationstumorimmunterapi
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
US10590457B2 (en) 2015-02-11 2020-03-17 Bristol Myers-Squibb Company Compositions for cell culture and methods of using the same
US11434264B2 (en) 2015-02-13 2022-09-06 Quanterix Corporation Immunoassays for differential detection of clostridium difficile
EP3978929A1 (de) 2015-02-19 2022-04-06 Compugen Ltd. Pvrig-polypeptide und verfahren zur behandlung
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
TWI719970B (zh) 2015-03-23 2021-03-01 美商永斯醫療股份有限公司 針對ｉｃｏｓ之抗體
BR112017020864A2 (en) 2015-03-30 2018-07-10 Dyax Corp. plasma kallikrein inhibitors and their uses for the prevention of hereditary angioedema attack
KR102261618B1 (ko) 2015-03-31 2021-06-04 메디뮨 리미티드 신규한 il33 형태, il33의 돌연변이된 형태, 항체, 검정 및 이의 이용 방법
EA201792184A1 (ru) 2015-04-01 2018-04-30 Анаптисбайо, Инк. Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3)
AU2016239858B2 (en) 2015-04-02 2021-07-01 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
RS61907B1 (sr) 2015-04-06 2021-06-30 Subdomain Llc Polipeptidi koji sadrže de novo vezujući domen i njihova primena
US10849992B1 (en) 2015-04-07 2020-12-01 Alector Llc Methods of screening for sortilin binding antagonists
CN107708733B (zh) 2015-04-07 2022-11-15 艾利妥 抗分拣蛋白抗体和其使用方法
EP3283520B1 (de) 2015-04-13 2020-05-06 Pfizer Inc Chimäre antigenrezeptoren zum targeting des b-zell-reifungsantigens
PL3988117T3 (pl) 2015-04-13 2025-03-10 Pfizer Inc. Przeciwciała terapeutyczne i ich zastosowania
WO2016165762A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016165765A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
WO2016168542A1 (en) 2015-04-15 2016-10-20 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)
WO2016170447A1 (en) 2015-04-24 2016-10-27 Rinat Neuroscience Corp. Recombinant microbial transglutaminases
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
CA2984794A1 (en) 2015-05-07 2016-11-10 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
TN2019000101A1 (en) 2015-05-29 2020-07-15 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof.
MA44594B1 (fr) 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
CN113480640B (zh) 2015-06-01 2024-07-30 免疫医疗有限责任公司 中和抗流感结合分子及其用途
JP7497953B2 (ja) 2015-06-12 2024-06-11 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
JP7376977B2 (ja) 2015-06-12 2023-11-09 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
US10774145B2 (en) 2015-06-17 2020-09-15 Allakos Inc. Methods and compositions for treating fibrotic diseases
UY36751A (es) 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
AU2016285920A1 (en) 2015-06-29 2018-02-01 Bristol-Myers Squibb Company Antibodies to CD40 with enhanced agonist activity
DK3322733T3 (da) 2015-07-13 2021-10-18 Compugen Ltd Hide1-sammensætninger og fremgangsmåder
CN116333144A (zh) 2015-07-21 2023-06-27 武田药品工业株式会社 一种因子xiia的单克隆抗体抑制剂
WO2017015619A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
CA2995838A1 (en) 2015-08-19 2017-02-23 Rutgers, The State University Of New Jersey Novel methods of generating antibodies
JP6664467B2 (ja) 2015-08-19 2020-03-13 ファイザー・インク 組織因子経路インヒビター抗体およびその使用
CA2996059A1 (en) 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
EP3341415B1 (de) 2015-08-28 2021-03-24 H. Hoffnabb-La Roche Ag Anti-hypusin-antikörper und verwendungen davon
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
US10633445B2 (en) 2015-09-15 2020-04-28 Board Of Regents The University Of Texas System T-cell receptor (TCR)-binding antibodies and uses thereof
NZ741324A (en) 2015-09-21 2021-09-24 Erasmus Univ Medical Center Anti-cd47 antibodies and methods of use
RU2638457C2 (ru) 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
PL3368572T3 (pl) 2015-10-02 2022-09-12 Symphogen A/S Przeciwciała anty-PD-1 oraz kompozycje
AU2016334051B2 (en) 2015-10-06 2023-10-26 Alector Llc Anti-TREM2 antibodies and methods of use thereof
WO2017066714A1 (en) 2015-10-16 2017-04-20 Compugen Ltd. Anti-vsig1 antibodies and drug conjugates
CN108290939B (zh) 2015-10-16 2023-01-13 纽约市哥伦比亚大学理事会 用于抑制谱系特异性抗原的组合物和方法
EP3365372A1 (de) 2015-10-22 2018-08-29 Jounce Therapeutics, Inc. Gensignaturen zur bestimmung der icos-expression
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
KR102876923B1 (ko) 2015-10-23 2025-10-28 화이자 인코포레이티드 항-il-2 항체 및 조성물 및 이의 용도
CA3003458A1 (en) 2015-10-29 2017-05-04 Alector Llc Anti-siglec-9 antibodies and methods of use thereof
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
CN108350416A (zh) 2015-11-09 2018-07-31 百时美施贵宝公司 操纵在cho细胞中产生的多肽的品质属性的方法
MA43260A (fr) 2015-11-18 2018-09-26 Merck Sharp & Dohme Liants pd1 et/ou lag3
CR20180279A (es) 2015-11-18 2018-08-24 Merck Sharp & Dohme Enlazadores de ctla4
US10544222B2 (en) 2015-11-18 2020-01-28 Merck Sharp & Dohme Corp. PD1/CTLA4 binders
CA3005906A1 (en) 2015-11-19 2017-05-26 Shire Human Genetic Therapies, Inc. Recombinant human c1 esterase inhibitor and uses thereof
BR112018010172A2 (pt) 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
EP3383904A4 (de) 2015-11-19 2019-12-04 Zeling Cai Ctla-4-antikörper und verwendungen davon
WO2017095875A1 (en) 2015-11-30 2017-06-08 Bristol-Myers Squibb Company Anti human ip-10 antibodies and their uses
SG11201804648RA (en) 2015-12-04 2018-06-28 Univ Texas Slc45a2 peptides for immunotherapy
AU2016366557B2 (en) 2015-12-11 2024-01-25 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
KR20180086502A (ko) 2015-12-16 2018-07-31 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항원-결합 단편
WO2017102920A1 (en) 2015-12-18 2017-06-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
SG11201805557SA (en) 2016-01-08 2018-07-30 Bioalliance Cv Tetravalent anti-psgl-1 antibodies and uses thereof
EA201891641A1 (ru) 2016-01-21 2019-01-31 Пфайзер Инк. Химерные антигенные рецепторы, нацеленные на вариант iii рецептора эпидермального фактора роста
US10221242B2 (en) 2016-01-21 2019-03-05 Pfizer Inc. Antibodies specific for epidermal growth factor receptor variant III and their uses
JP2019511911A (ja) 2016-02-17 2019-05-09 ノバルティス アーゲー Ｔｇｆベータ２抗体
WO2017152102A2 (en) 2016-03-04 2017-09-08 Alector Llc Anti-trem1 antibodies and methods of use thereof
ES2985566T3 (es) 2016-03-04 2024-11-06 Univ Rockefeller Anticuerpos contra CD40 con actividad agonista mejorada
KR20230038311A (ko) 2016-03-04 2023-03-17 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
AU2017231108B2 (en) 2016-03-08 2021-06-17 KeMyth Biotech Co., Ltd. Use of pneumolysin peptides as antagonists against toll-like receptor 4 and methods of treating toll-like receptor 4 related diseases
RU2756109C2 (ru) 2016-03-10 2021-09-28 Виела Байо, Инк. Связывающие ilt7 молекулы и способы их применения
EP3432925A4 (de) 2016-03-22 2019-11-06 Bionomics Limited Verabreichung eines monoklonalen anti-lgr5-antikörpers
CA3018365A1 (en) 2016-03-23 2017-09-28 The General Hospital Corporation Assays and methods for detecting udp-glucose
AU2017241776B2 (en) 2016-03-29 2024-06-20 Janssen Biotech, Inc. Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody
TN2018000333A1 (en) 2016-04-12 2020-01-16 Symphogen As Anti-tim-3 antibodies and compositions
US12297266B2 (en) 2016-04-18 2025-05-13 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof
CA3019588A1 (en) 2016-04-20 2017-10-26 Merck Sharp & Dohme Corp. Cmv neutralizing antigen binding proteins
JP2019516362A (ja) 2016-04-27 2019-06-20 ファイザー・インク 抗ｉｌ−３３抗体、その組成物、方法および使用
AU2017258492B2 (en) 2016-04-29 2023-12-07 Pfizer Inc. Interferon beta antibodies and uses thereof
KR102417687B1 (ko) 2016-05-09 2022-07-07 브리스톨-마이어스 스큅 컴퍼니 Tl1a 항체 및 그의 용도
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
TWI781934B (zh) 2016-05-27 2022-11-01 美商艾吉納斯公司 抗-tim-3抗體及其使用方法
US10851159B2 (en) 2016-06-02 2020-12-01 Bloom Diagnostics Ag Antibodies that bind to human anti-Müllerian hormone (AMH) and their uses
SG11201810640RA (en) 2016-06-08 2018-12-28 Intrexon Corp Cd33 specific chimeric antigen receptors
AU2017292184A1 (en) 2016-07-08 2019-02-07 Staten Biotechnology B.V. Anti-Apoc3 antibodies and methods of use thereof
JP7149257B2 (ja) 2016-07-13 2022-10-06 バイオジェン・エムエイ・インコーポレイテッド Ｌｉｎｇｏ－１アンタゴニストの投与計画及び脱髄障害の処置のための使用
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
MY200602A (en) 2016-07-14 2024-01-04 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
JP2019524721A (ja) 2016-07-15 2019-09-05 ポセイダ セラピューティクス， インコーポレイテッド キメラ抗原受容体および使用方法
MX2019000641A (es) 2016-07-15 2019-06-10 Poseida Therapeutics Inc Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso.
WO2018023113A1 (en) 2016-07-29 2018-02-01 New York University Treating solid tumor by targeting dectin-1 signaling
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
CN110088132B (zh) 2016-08-17 2020-10-27 康姆普根有限公司 抗tigit抗体，抗pvrig抗体及其组合
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
KR102543878B1 (ko) 2016-08-23 2023-06-14 메디뮨 리미티드 항-ｖｅｇｆ-ａ 및 항-ａｎｇ2 항체 및 이의 용도
KR102538827B1 (ko) 2016-08-23 2023-05-31 메디뮨 리미티드 항-ｖｅｇｆ-ａ 항체 및 이의 용도
WO2018054484A1 (en) 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
SG11201901959YA (en) 2016-09-30 2019-04-29 Poseida Therapeutics Inc Modified stem cell memory t cells, methods of making and methods of using same
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
EP3519049B1 (de) 2016-09-30 2025-12-03 Janssen Biotech, Inc. Sicheres und effizientes verfahren zur behandlung von psoriasis mit anti-il23-spezifischem antikörper
PT3523325T (pt) 2016-10-06 2025-11-12 Poseida Therapeutics Inc Caspases induzíveis e métodos de utilização
SG10201912663YA (en) 2016-10-11 2020-03-30 Agenus Inc Anti-lag-3 antibodies and methods of use thereof
SG10201912925SA (en) 2016-10-13 2020-02-27 Massachusetts Inst Technology Antibodies that bind zika virus envelope protein and uses thereof
MY203971A (en) 2016-10-13 2024-07-26 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anti-lag-3 antibodies and compositions
WO2018081649A1 (en) 2016-10-28 2018-05-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
CA3041684C (en) 2016-11-01 2023-09-26 Anaptysbio, Inc. Antibodies directed against programmed death- 1 (pd-1)
SG11201903867YA (en) 2016-11-01 2019-05-30 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
HUE057559T2 (hu) 2016-11-02 2022-06-28 Jounce Therapeutics Inc PD-1 elleni antitestek és alkalmazásaik
WO2018083538A1 (en) 2016-11-07 2018-05-11 Neuracle Scienc3 Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
MX2019005661A (es) 2016-11-16 2019-10-07 Janssen Biotech Inc Método para tratar la psoriasis con el anticuerpo específico anti-il23.
US12173340B2 (en) 2016-11-16 2024-12-24 Agency For Science, Technology And Research Attenuated glutamine synthetase as a selection marker
TWI780083B (zh) 2016-11-18 2022-10-11 丹麥商賽門弗鎮公司 抗pd-1抗體及組成物
US10759855B2 (en) 2016-12-02 2020-09-01 Rigel Pharmaceuticals, Inc. Antigen binding molecules to TIGIT
WO2018106862A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
IL267538B2 (en) 2016-12-23 2024-05-01 Novartis Ag Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient
MX2019008208A (es) 2017-01-09 2019-12-11 Tesaro Inc Métodos para tratar el cáncer con anticuerpos anti-tim-3.
PT3565844T (pt) 2017-01-09 2023-05-02 Tesaro Inc Métodos de tratamento de cancro com anticorpos anti-pd-1
KR20190102259A (ko) 2017-01-10 2019-09-03 인트렉손 코포레이션 신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
WO2018132516A1 (en) 2017-01-10 2018-07-19 Nodus Therapeutics Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
CN117586401A (zh) 2017-01-20 2024-02-23 大有华夏生物医药集团有限公司 抗pd-1抗体及其用途
KR20190113858A (ko) 2017-01-30 2019-10-08 얀센 바이오테크 인코포레이티드 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
MA47442A (fr) 2017-02-07 2019-12-18 Janssen Biotech Inc Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
US10828330B2 (en) 2017-02-22 2020-11-10 IO Bioscience, Inc. Nucleic acid constructs comprising gene editing multi-sites and uses thereof
US12440578B2 (en) 2017-02-22 2025-10-14 Io Biosciences, Inc. Nucleic acid constructs comprising gene editing multi-sites and uses thereof
RU2019127550A (ru) 2017-03-03 2021-04-05 Ринат Ньюросайенс Корп. Анти-gitr антитела и способы их использования
AU2018235756B2 (en) 2017-03-13 2024-08-08 Poseida Therapeutics, Inc. Compositions and methods for selective elimination and replacement of hematopoietic stem cells
EP3596206A1 (de) 2017-03-16 2020-01-22 Pfizer Inc Tyrosinprototrophie
FI3600415T3 (fi) 2017-03-24 2025-12-05 Novartis Ag Aktiviinireseptorin tyypin ii reseptorin vastainen vasta-aine käytettäväksi sydämen vajaatoiminnan hoidossa
US20200024351A1 (en) 2017-04-03 2020-01-23 Jounce Therapeutics, Inc. Compositions and Methods for the Treatment of Cancer
EA201992350A1 (ru) 2017-04-05 2020-03-23 Симфоген А/С Комбинированные лекарственные средства, нацеленные на pd-1, tim-3 и lag-3
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
US20230192839A1 (en) 2017-04-12 2023-06-22 Pfizer Inc. Antibodies having conditional affinity and methods of use thereof
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗ｃｄ１３７抗体およびその使用方法
CN118267470A (zh) 2017-04-13 2024-07-02 赛罗帕私人有限公司 抗SIRPα抗体
RU2665790C1 (ru) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
BR112019021857A2 (pt) 2017-04-19 2020-06-02 Allogene Therapeutics, Inc. Métodos e composições de célula t aperfeiçoada
JP2020517242A (ja) 2017-04-21 2020-06-18 スターテン・バイオテクノロジー・ベー・フェー 抗ＡｐｏＣ３抗体およびその使用方法
KR102637960B1 (ko) 2017-04-22 2024-02-21 이뮤노믹 쎄라퓨틱스, 인크. 개선된 lamp 구축물
WO2018200620A1 (en) 2017-04-25 2018-11-01 National Cheng Kung University Use of il-20 antagonists for treating eye diseases
EP3615070A1 (de) 2017-04-26 2020-03-04 Bristol-Myers Squibb Company Verfahren zur antikörperproduktion mit minimaler disulfidbindungsreduzierung
RS64576B1 (sr) 2017-05-01 2023-10-31 Agenus Inc Anti-tigit antitela i postupci njihove primene
US12358962B2 (en) 2017-05-02 2025-07-15 Immunomic Therapeutics, Inc. Lamp constructs comprising cancer antigens
KR20200016232A (ko) 2017-05-05 2020-02-14 알라코스 인크. 알레르기성 안구 질환을 치료하기 위한 방법 및 조성물
WO2018204895A1 (en) 2017-05-05 2018-11-08 Vaccinex, Inc. Human anti-semaphorin 4d antibody
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2018213316A1 (en) 2017-05-16 2018-11-22 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
EP3625253A4 (de) 2017-05-16 2021-03-24 Scalmibio, Inc. Aktivierbare antikörper und verfahren zur verwendung davon
JP7486953B2 (ja) 2017-05-18 2024-05-20 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー 細胞標的化療法のための組成物および方法
ES2926722T3 (es) 2017-05-26 2022-10-27 Abvitro Llc Secuenciación de alto rendimiento de biblioteca de polinucleótidos y análisis de transcriptoma
BR112019024742A2 (pt) 2017-06-02 2020-06-16 Pfizer Inc. Proteínas robo2 recombinantes, composições, métodos e usos das mesmas
JP7317718B2 (ja) 2017-06-02 2023-07-31 ファイザー・インク Ｆｌｔ３を標的にするキメラ抗原受容体
CN118772278A (zh) 2017-06-02 2024-10-15 辉瑞公司 Flt3的特异性抗体及其用途
EP3635132A4 (de) 2017-06-07 2021-05-26 Intrexon Corporation Expression von neuartigen zellmarkern
US11365253B2 (en) 2017-06-09 2022-06-21 Pfizer Inc. Anti-ROBO2 antibodies, compositions, methods and uses thereof
AU2018287317B2 (en) 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof
JP7076059B2 (ja) 2017-06-27 2022-05-27 ニューラクル サイエンス カンパニー リミテッド 抗ｆａｍ１９ａ５抗体及びその用途
EP3645564A1 (de) 2017-06-28 2020-05-06 Novartis AG Verfahren zur prävention und behandlung von harninkontinenz
JP2020526584A (ja) 2017-06-28 2020-08-31 ザ ロックフェラー ユニバーシティー 抗ｍｅｒｔｋアゴニスト抗体−薬物コンジュゲートおよびその使用
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
CN111032694B (zh) 2017-07-14 2024-03-08 辉瑞大药厂 针对madcam的抗体
WO2019018647A1 (en) 2017-07-20 2019-01-24 Pfizer Inc. ANTI-GD3 ANTIBODIES AND CONJUGATES ANTIBODY-MEDICATION
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra ANTI-NUCLEOLIN ANTIBODIES
KR102733407B1 (ko) 2017-08-03 2024-11-21 알렉터 엘엘씨 항-cd33 항체 및 이의 이용 방법
BR112019022752A2 (pt) 2017-08-03 2020-05-19 Alector Llc anticorpos anti-trem2 e métodos de uso dos mesmos
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
US20200199192A1 (en) 2017-08-22 2020-06-25 Shire-Nps Pharmaceuticals, Inc. Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
EP3672990A1 (de) 2017-08-25 2020-07-01 Five Prime Therapeutics, Inc. B7-h4-antikörper und verfahren zur verwendung davon
WO2019048040A1 (en) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
EP3679370A1 (de) 2017-09-07 2020-07-15 Juno Therapeutics, Inc. Verfahren zur identifizierung von zellulären attributen im zusammenhang mit den ergebnissen einer zelltherapie
AU2018329741B2 (en) 2017-09-08 2025-02-20 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression
JP7023942B2 (ja) 2017-09-20 2022-03-03 豊宥科技股▲フン▼有限公司 卵巣癌バイオマーカーおよびその使用
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
RU2698048C2 (ru) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
EA039662B1 (ru) 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
CN119930795A (zh) 2017-10-12 2025-05-06 得克萨斯大学体系董事会 用于免疫疗法的t细胞受体
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
JP7324749B2 (ja) 2017-10-27 2023-08-10 ファイザー・インク Ｃｄ１２３に特異的な抗体および抗体－薬物コンジュゲートならびにその使用
IL312910B1 (en) 2017-10-27 2026-02-01 Univ New York Anti-galectin-9 antibodies and their uses
KR20200074975A (ko) 2017-10-31 2020-06-25 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
JP7261232B2 (ja) 2017-11-01 2023-04-19 アロジーン セラピューティクス，インコーポレイテッド 改変カスパーゼ－９ポリペプチドおよびその使用方法
AU2018361743A1 (en) 2017-11-03 2020-04-09 Novartis Ag Anti-CD40 antibodies for use in treatment of Sjogren's syndrome
IL274272B2 (en) 2017-11-06 2025-09-01 Janssen Biotech Inc A safe and effective method for treating psoriatic arthritis with a specific anti-IL23 antibody
AU2018369639C1 (en) 2017-11-14 2025-04-03 Arcellx, Inc. D-domain containing polypeptides and uses thereof
IL274677B2 (en) 2017-11-14 2025-01-01 Arcellx Inc Therapies with multifunctional immune system cells
US20200299349A1 (en) 2017-11-21 2020-09-24 The Board Of Trustees Of The Leland Stanford Junior University Partial agonists of interleukin-2
MX2020005662A (es) 2017-12-01 2020-08-20 Pfizer Anticuerpos anti-cxcr5 y composiciones y usos de los mismos.
KR20200091901A (ko) 2017-12-01 2020-07-31 시애틀 지네틱스, 인크. 암을 치료하기 위한 cd47 항체 및 이의 용도
KR102752985B1 (ko) 2017-12-20 2025-01-10 포세이다 테라퓨틱스, 인크. Vcar 조성물 및 사용 방법
EP4219559A3 (de) 2017-12-22 2023-10-18 Jounce Therapeutics, Inc. Antikorper gegen lilrb2
CN111788227B (zh) 2017-12-27 2025-02-25 百时美施贵宝公司 抗cd40抗体及其用途
KR20250078626A (ko) 2018-01-12 2025-06-02 브리스톨-마이어스 스큅 컴퍼니 Tim3에 대한 항체 및 그의 용도
KR102780406B1 (ko) 2018-02-01 2025-03-17 화이자 인코포레이티드 Cd70을 표적으로 하는 키메라 항원 수용체
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
PE20210708A1 (es) 2018-02-01 2021-04-16 Pfizer Anticuerpos especificos para cd70 y sus usos
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
ES2992014T3 (es) 2018-02-12 2024-12-05 Tufts College CD59 para inhibir la activación del inflamasoma
US12246031B2 (en) 2018-02-13 2025-03-11 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
JP2021514379A (ja) 2018-02-21 2021-06-10 ファイブ プライム セラピューティクス， インコーポレイテッド Ｂ７−ｈ４抗体製剤
JP2021516045A (ja) 2018-02-28 2021-07-01 ファイザー・インク Ｉｌ−１５バリアントおよびその使用
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
WO2019169290A1 (en) 2018-03-02 2019-09-06 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
MA52416A (fr) 2018-03-02 2021-04-21 Five Prime Therapeutics Inc Anticorps b7-h4 et leurs procédés d'utilisation
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CA3092551A1 (en) 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
WO2019173465A1 (en) 2018-03-06 2019-09-12 Intrexon Corporation Human papillomavirus vaccines and uses of the same
KR102849343B1 (ko) 2018-03-07 2025-08-25 포세이다 테라퓨틱스, 인크. Cartyrin 조성물 및 사용 방법
PE20210665A1 (es) 2018-03-23 2021-03-31 Bristol Myers Squibb Co Anticuerpos contra mica y/o micb y sus usos
CA3094756A1 (en) 2018-03-29 2019-10-03 Pfizer Inc. Lfa3 variants and compositions and uses thereof
KR102890791B1 (ko) 2018-04-09 2025-11-24 체크메이트 파마슈티칼스, 인크. 바이러스-유사 입자 내로의 올리고뉴클레오타이드의 포장
US10654944B2 (en) 2018-04-10 2020-05-19 Y-Biologics Inc. Cell engaging binding molecules
CN112004558A (zh) 2018-04-12 2020-11-27 米迪亚制药有限责任公司 Lgals3bp抗体-药物-偶联物及其用于癌症的治疗的用途
JP6861301B2 (ja) 2018-04-13 2021-04-21 ノバルティス アーゲー 移植片拒絶の予防に使用するための抗ｃｄ４０抗体
US11459393B2 (en) 2018-04-17 2022-10-04 Celldex Therapeutics, Inc. Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
LT3781941T (lt) 2018-04-20 2026-04-10 Janssen Biotech, Inc. Chromatografijos kolonėlės kvalifikavimas gamybos būduose, skirtuose anti-tnf antikūnų kompozicijoms gaminti
BR112020021855A2 (pt) 2018-04-27 2021-02-23 Biogen Ma Inc. anticorpo antirrepetição de dipeptídeo (dpr) (poli-ga) derivado de humanos
WO2019217455A1 (en) 2018-05-07 2019-11-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
WO2019217457A1 (en) 2018-05-07 2019-11-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
CA3098805A1 (en) 2018-05-10 2019-11-14 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
MX2020012081A (es) 2018-05-11 2021-04-28 Wuxi Biologics Shanghai Co Ltd Anticuerpos totalmente humanos contra ox40, metodo para preparar los mismos y su uso.
CA3100005A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
WO2019219979A1 (en) 2018-05-18 2019-11-21 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
MX2020012607A (es) 2018-05-23 2021-01-29 Pfizer Anticuerpos especificos para gucy2c y sus usos.
SI3797121T1 (sl) 2018-05-23 2024-09-30 Pfizer Inc. Protitelesa, specifična za CD3, in njihova uporaba
US20210196834A1 (en) 2018-05-30 2021-07-01 Abbvie Stemcentrx Llc Anti-sez6 antibody drug conjugates and methods of use
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
KR20210056288A (ko) 2018-06-01 2021-05-18 타유 후아시아 바이오테크 메디컬 그룹 컴퍼니 리미티드 질환 또는 병태를 치료하기 위한 조성물 및 그의 용도
US12037398B2 (en) 2018-06-04 2024-07-16 Biogen Ma Inc. Anti-VLA-4 antibodies having reduced effector function
MX2020013172A (es) 2018-06-08 2021-03-29 Alector Llc Anticuerpos anti-siglec-7 y sus metodos de uso.
US12006357B2 (en) 2018-06-26 2024-06-11 Mor Research Applications Ltd. Transthyretin antibodies and uses thereof
WO2020003210A1 (en) 2018-06-29 2020-01-02 Kangwon National University University-Industry Cooperation Foundation Anti-l1cam antibodies and uses thereof
TWI809147B (zh) 2018-07-13 2023-07-21 美商阿列克特有限責任公司 抗分揀蛋白抗體及其使用方法
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
CN112424231B (zh) 2018-07-19 2022-09-13 大有华夏生物医药集团有限公司 抗pd-1抗体及其剂量和用途
JP7535495B2 (ja) 2018-07-27 2024-08-16 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－５抗体及びその使用方法
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
JP7155403B2 (ja) 2018-08-20 2022-10-18 ファイザー・インク 抗ｇｄｆ１５抗体、組成物および使用の方法
WO2020041360A1 (en) 2018-08-21 2020-02-27 Quidel Corporation Dbpa antibodies and uses thereof
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
US20200109214A1 (en) 2018-08-30 2020-04-09 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
MX2021002299A (es) 2018-08-31 2021-04-28 Alector Llc Anticuerpos de anti-cd33 y metodos para usarlos.
EP3847197A1 (de) 2018-09-05 2021-07-14 Poseida Therapeutics, Inc. Zusammensetzungen allogener zellen und verfahren zur verwendung
US11359024B2 (en) 2018-09-07 2022-06-14 Pfizer Inc. Anti-AVB8 antibodies and compositions and uses thereof
US12097219B2 (en) 2018-09-10 2024-09-24 Legend Biotech Ireland Limited Single-domain antibodies against CLL1 and constructs thereof
RU2706298C1 (ru) 2018-09-14 2019-11-15 Закрытое Акционерное Общество "Биокад" НУКЛЕАЗА PaCas9
BR112021005467A2 (pt) 2018-09-24 2021-06-22 Janssen Biotech, Inc. método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23
CN120463822A (zh) 2018-09-27 2025-08-12 西里欧发展公司 掩蔽型细胞因子多肽
WO2020070678A2 (en) 2018-10-03 2020-04-09 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
CN112805301B (zh) 2018-10-15 2023-07-21 安立玺荣生医(香港)有限公司 粒细胞-巨噬细胞集落刺激因子的抗体及其用途
GB201816919D0 (en) 2018-10-17 2018-11-28 Glaxosmithkline Ip Dev Ltd Adeno-associated viral vector producer cell lines
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
RU2724469C2 (ru) 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с cd20
EP3876977A1 (de) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimäre antigen-rezeptoren für phagocytose
US11274150B2 (en) 2018-11-16 2022-03-15 Bristol-Myers Squibb Company Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
EP3887393A1 (de) 2018-11-26 2021-10-06 Novartis AG Lpl-gpihbp1 fusionspolypeptide
CA3119799A1 (en) 2018-12-04 2020-06-11 Catalent Pharma Solutions, Llc Vectors for protein manufacture
US20200197517A1 (en) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
TW202039554A (zh) 2018-12-19 2020-11-01 瑞士商諾華公司 抗ＴＮＦ－α抗體
US20220042038A1 (en) 2018-12-20 2022-02-10 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
WO2020132190A1 (en) 2018-12-21 2020-06-25 Multitude Inc. Antibodies specific to muc18
BR112021012536A2 (pt) 2018-12-26 2021-09-14 City Of Hope Proteínas de ligação anti-ctla4 mascaradas ativáveis
CA3117619A1 (en) 2019-01-02 2020-07-09 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
WO2020144605A1 (en) 2019-01-11 2020-07-16 Novartis Ag Anti-cd40 antibodies for use in treatment of hidradenitis suppurativa
MA54750A (fr) 2019-01-15 2021-11-24 Janssen Biotech Inc Compositions d'anticorps anti-tnf et procédés pour le traitement de l'arthrite idiopathique juvénile
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
US11008395B2 (en) 2019-01-22 2021-05-18 Bristol Myers-Squibb Company Antibodies against IL-7R alpha subunit and uses thereof
BR112021014267A2 (pt) 2019-01-23 2022-02-15 Janssen Biotech Inc Composições de anticorpo anti-tnf e métodos para o tratamento de artrite psoriática
US12084500B2 (en) 2019-01-23 2024-09-10 New York University Antibodies specific to delta 1 chain of T cell receptor
WO2020151572A1 (en) 2019-01-23 2020-07-30 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-pd-l1 diabodies and the use thereof
JP2020117502A (ja) 2019-01-28 2020-08-06 ファイザー・インク 変形性関節症の徴候および症状を処置する方法
KR20210121137A (ko) 2019-01-29 2021-10-07 샤이어-엔피에스 파마슈티칼즈, 인크. 부갑상선 호르몬 변이체
WO2020163225A1 (en) 2019-02-05 2020-08-13 Seattle Genetics, Inc. Anti-cd228 antibodies and antibody-drug conjugates
AU2020221821A1 (en) 2019-02-13 2021-08-26 The Brigham And Women's Hospital, Inc. Anti-peripheral lymph node addressin antibodies and uses thereof
JP2020143045A (ja) 2019-02-18 2020-09-10 ファイザー・インク 慢性腰背部疼痛の処置の方法
MA55080A (fr) 2019-02-26 2022-01-05 Inspirna Inc Anticorps anti-mertk à affinité élevée et utilisations associées
US10570210B1 (en) 2019-03-04 2020-02-25 Beijing Mabworks Biotech Co.Ltd Antibodies binding CD40 and uses thereof
EP3938396A1 (de) 2019-03-11 2022-01-19 Jounce Therapeutics, Inc. Anti-icos-antikörper zur behandlung von krebs
KR20210141990A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-il12/il23 항체 조성물을 생성하기 위한 제조 방법
KR20210141976A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물의 제조 방법
JP7662529B2 (ja) 2019-03-14 2025-04-15 ヤンセン バイオテツク，インコーポレーテツド 抗ｔｎｆ抗体組成物を産生するための方法
CA3133381A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
MX2021011328A (es) 2019-03-18 2021-12-10 Janssen Biotech Inc Método para tratar la psoriasis en sujetos pediátricos con anticuerpo anti-il12/il23.
RU2734432C1 (ru) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
WO2020225736A1 (en) 2019-05-08 2020-11-12 Novartis Ag Anti-cd40 antibodies for use in treatment of t1dm and insulitis
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
WO2020234834A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
AU2020283906A1 (en) 2019-05-31 2022-01-20 Trustees Of Tufts College Anti-ADAM8 antibodies and uses of the same
US20220324959A1 (en) 2019-06-03 2022-10-13 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
MA56015A (fr) 2019-06-03 2022-04-06 Janssen Biotech Inc Compositions d'anticorps anti-tnf et méthodes pour le traitement de l'arthrite psoriasique
MX2021014953A (es) 2019-06-04 2022-01-24 Janssen Biotech Inc Metodo seguro y eficaz para tratar la artritis psoriasica con el anticuerpo especifico anti-il23.
CN114206943A (zh) 2019-06-04 2022-03-18 分子伴侣公司 多特异性蛋白质
US20220306727A1 (en) 2019-06-05 2022-09-29 Seagen Inc. Methods of Purifying Masked Antibodies
US20220233709A1 (en) 2019-06-05 2022-07-28 Seagen Inc. Masked Antibody Formulations
US20220235132A1 (en) 2019-06-05 2022-07-28 Anaptysbio, Inc. Pd-1 agonist and method of using same
EA202193345A1 (ru) 2019-06-12 2022-03-16 Новартис Аг Антитела к рецептору-1 натрийуретического пептида и способы их применения
CA3144871A1 (en) 2019-06-27 2020-12-30 Crispr Therapeutics Ag Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
AU2020300002A1 (en) 2019-07-01 2022-02-24 Tonix Pharma Limited Anti-CD154 antibodies and uses thereof
CN114174337B (zh) 2019-07-15 2024-10-25 英特维特国际股份有限公司 针对犬ctla-4的犬源化抗体
CA3145347A1 (en) 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies to human and canine ctla-4
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CN114867751B (zh) 2019-08-12 2024-11-29 阿帕特夫研究和发展有限公司 4-1bb和ox40结合蛋白及相关组合物和方法、抗-4-1bb抗体、抗-ox40抗体
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
TW202122420A (zh) 2019-08-30 2021-06-16 美商艾吉納斯公司 抗ｃｄ９６抗體及其使用方法
CN114761424B (zh) 2019-09-05 2025-09-19 波赛达治疗公司 同种异体细胞组合物和使用方法
MX2022003009A (es) 2019-09-11 2022-06-14 Novartis Ag Metodo para prevenir trastornos asociados a virus humanos en pacientes.
RU2753282C2 (ru) 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
GB201913697D0 (en) 2019-09-23 2019-11-06 King S College London DAP10/DAP12 fusion polypeptides
WO2021058091A1 (en) 2019-09-24 2021-04-01 Biontech Rna Pharmaceuticals Gmbh Treatment involving therapeutic antibody and interleukin-2 (il2)
AU2020358859A1 (en) 2019-10-04 2022-05-12 Seagen Inc. Anti-PD-L1 antibodies and antibody-drug conjugates
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021072244A1 (en) 2019-10-11 2021-04-15 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
EP4045528A1 (de) 2019-10-18 2022-08-24 Immunomic Therapeutics, Inc. Verbesserte lampenkonstrukte, die krebsantigene umfassen
WO2021079002A2 (en) 2019-10-24 2021-04-29 Novago Therapeutics Ag Novel anti-nogo-a antibodies
AU2020379001A1 (en) 2019-11-04 2022-06-09 Paul RUBINSTEIN Anti-CD30 antibody-drug conjugates and their use for the treatment of HIV infection
EP4055052A1 (de) 2019-11-05 2022-09-14 Jounce Therapeutics, Inc. Verfahren zur behandlung von krebs mit anti-pd-1-antikörpern
AU2020378263A1 (en) 2019-11-05 2022-06-23 Janssen Biotech, Inc. BCMA-targeted CAR-T cell therapy of multiple myeloma
MX2022005222A (es) 2019-11-07 2022-06-08 Genmab As Metodos para tratar el cancer con una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y un conjugado de anticuerpo anti factor tisular-farmaco.
TW202131954A (zh) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
MX2022006073A (es) 2019-12-05 2022-08-04 Alector Llc Metodos para utilizar anticuerpos anti-trem2.
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
EP4073119A1 (de) 2019-12-12 2022-10-19 Alector LLC Verfahren zur verwendung von anti-cd33-antikörpern
JP7369297B2 (ja) 2019-12-17 2023-10-25 ファイザー・インク Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用
US20230053131A1 (en) 2019-12-20 2023-02-16 Intervet Inc. Antibodies to canine interleukin-4 receptor alpha
CA3162246A1 (en) 2019-12-20 2021-06-24 Poseida Therapeutics, Inc. Anti-muc1 compositions and methods of use
MX2022007636A (es) 2019-12-20 2022-07-19 Intervet Int Bv Anticuerpos biespecificos caninizados y pares de union biespecificos para el tratamiento contra dermatitis atopica.
CN113045655A (zh) 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 抗ox40抗体及其用途
TWI877278B (zh) 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
JP7456075B2 (ja) 2020-01-03 2024-03-27 ビオシオン インコーポレイテッド 抗体結合ｂｃｍａ及びその使用
US12528880B2 (en) 2020-01-13 2026-01-20 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
EP4090674A4 (de) 2020-01-14 2024-01-24 Synthekine, Inc. Vorgespannte il2-muteins-verfahren und -zusammensetzungen
IL294818A (en) 2020-01-21 2022-09-01 Bolt Biotherapeutics Inc Anti-pd-l1 antibodies
JP2023511363A (ja) 2020-01-21 2023-03-17 ボルト バイオセラピューティクス、インコーポレーテッド 坑ｐｄ－ｌ１抗体
JP7449390B2 (ja) 2020-01-24 2024-03-13 ファイザー・インク 抗ｅ－セレクチン抗体、組成物および使用の方法
JP2023513282A (ja) 2020-02-11 2023-03-30 クリスパー セラピューティクス アクチェンゲゼルシャフト 抗ｃｄ１９キメラ抗原受容体を標的とする抗イディオタイプ抗体
KR20260017503A (ko) 2020-02-14 2026-02-05 길리애드 사이언시즈, 인코포레이티드 Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도
JP2023513834A (ja) 2020-02-18 2023-04-03 アレクトル エルエルシー Ｐｉｌｒａ抗体及びその使用方法
CA3167851A1 (en) 2020-02-24 2021-09-02 Francesca CIGNARELLA Methods of use of anti-trem2 antibodies
US20230105029A1 (en) 2020-02-27 2023-04-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Antibodies binding il4r and uses thereof
CA3169910A1 (en) 2020-02-28 2021-09-02 Shanghai Henlius Biotech, Inc. Anti-cd137 constructs, multispecific antibody and uses thereof
AU2021225920A1 (en) 2020-02-28 2022-09-15 Shanghai Henlius Biotech, Inc. Anti-CD137 construct and use thereof
US20230220085A1 (en) 2020-02-28 2023-07-13 The Brigham And Women’S Hospital, Inc. Selective modulation of transforming growth factor beta superfamily signaling via multi-specific antibodies
US12540335B2 (en) 2020-03-04 2026-02-03 Poseida Therapeutics, Inc. Compositions and methods for the treatment of metabolic liver disorders
GB202003277D0 (en) 2020-03-06 2020-04-22 King S College London Therapeutic agents
CA3174908A1 (en) 2020-03-09 2021-09-16 Pfizer Inc. Fusion proteins and uses thereof
WO2021183795A1 (en) 2020-03-11 2021-09-16 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
WO2021194951A1 (en) 2020-03-23 2021-09-30 Centivax, Inc. Anti-sars-cov-2 antibodies derived from 2dd8
FI4045533T3 (fi) 2020-03-26 2024-02-02 Univ Vanderbilt Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
CN115667308A (zh) 2020-04-03 2023-01-31 艾利妥 抗trem2抗体的使用方法
JP2023521667A (ja) 2020-04-04 2023-05-25 武田薬品工業株式会社 血漿カリクレイン阻害剤及び急性呼吸窮迫症候群を処置するためのその使用
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
WO2021211331A1 (en) 2020-04-13 2021-10-21 Abbott Point Of Care Inc. METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE
BR112022020650A2 (pt) 2020-04-14 2023-01-31 Poseida Therapeutics Inc Composições e métodos para uso no tratamento de câncer
AU2021260553A1 (en) 2020-04-20 2022-10-20 Jounce Therapeutics, Inc. Compositions and methods for vaccination and the treatment of infectious diseases
EP4143227A2 (de) 2020-04-30 2023-03-08 Sairopa B.V. Anti-cd103 antikörper
CR20220582A (es) 2020-05-01 2023-01-09 Bolt Biotherapeutics Inc Anticuerpos anti-dectina-2
EP4146273A4 (de) 2020-05-05 2024-07-31 Janssen Biotech, Inc. Verfahren zur behandlung von morbus crohn mit anti-il23-spezifischem antikörper
EP3909601A1 (de) 2020-05-11 2021-11-17 LeukoCom GmbH Neuer antikörper, der spezifisch an menschliches ceacam1/3/5 bindet, und dessen verwendung
MX2022014243A (es) 2020-05-12 2022-12-02 Chia Tai Tianqing Pharmaceutical Group Co Ltd Proteina de union al antigeno st2.
WO2021231798A1 (en) 2020-05-13 2021-11-18 Disc Medicine, Inc. Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
TW202200622A (zh) 2020-05-13 2022-01-01 瑞士商天演藥業公司 用於治療癌症之組成物及方法
IL298168A (en) 2020-05-14 2023-01-01 Molecular Partners Ag Multispecific proteins
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
AU2021275361A1 (en) 2020-05-17 2023-01-19 Astrazeneca Uk Limited SARS-CoV-2 antibodies and methods of selecting and using the same
KR20230023663A (ko) 2020-05-21 2023-02-17 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법
GB202007655D0 (en) 2020-05-22 2020-07-08 King S College London Chimeric nkg2d protein
US20230235075A1 (en) 2020-06-02 2023-07-27 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
US20230242624A1 (en) 2020-06-02 2023-08-03 Neurimmune Ag HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
US20210380707A1 (en) 2020-06-04 2021-12-09 Crispr Therapeutics Ag Anti-cd70 antibodies and uses thereof
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2021260657A1 (en) 2020-06-26 2021-12-30 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
MX2022015375A (es) 2020-06-29 2023-01-16 Genmab As Conjugados de farmaco-anticuerpo anti-factor de tejido y su uso en el tratamiento de cancer.
EP4175982A1 (de) 2020-06-30 2023-05-10 Fondazione Toscana Life Sciences Neutralisierende antikörper gegen sars-coronavirus-2
IT202000015754A1 (it) 2020-06-30 2021-12-30 Fond Toscana Life Sciences Antibodies to coronavirus
EP4178616A4 (de) 2020-07-13 2024-07-24 Janssen Biotech, Inc. Sicheres und wirksames verfahren zur behandlung von psoriasisarthritis mit anti-il23-spezifischem antikörper
MX2023000734A (es) 2020-07-14 2023-02-13 Pfizer Virus vaccinia recombinante.
TW202216779A (zh) 2020-07-17 2022-05-01 美商輝瑞股份有限公司 治療性抗體類和彼等之用途
AU2021313348A1 (en) 2020-07-20 2023-03-09 Astrazeneca Uk Limited SARS-CoV-2 proteins, anti-SARS-CoV-2 antibodies, and methods of using the same
EP4185610A2 (de) 2020-07-21 2023-05-31 Allogene Therapeutics, Inc. Chimäre antigenrezeptoren mit verbesserter signalisierung und aktivitäten sowie verwendungen davon
MX2023001055A (es) 2020-07-24 2023-03-17 Amgen Inc Inmunógenos derivados de la proteína de la espícula del sars-cov2.
TWI905235B (zh) 2020-07-29 2025-11-21 美商當康生物科技有限公司 抗cd93之構築體及其用途
JP2023536851A (ja) 2020-07-30 2023-08-30 アナプティスバイオ インコーポレイティッド 魚鱗癬のための抗インターロイキン３６受容体（ｉｌ－３６ｒ）療法
CA3190230A1 (en) 2020-07-30 2022-02-03 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
JP2023535604A (ja) 2020-07-30 2023-08-18 ファイザー・インク 遺伝子複製を有する細胞およびその使用
WO2022026829A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
WO2022031804A1 (en) 2020-08-04 2022-02-10 Abbott Laboratories Improved methods and kits for detecting sars-cov-2 protein in a sample
KR20230042518A (ko) 2020-08-04 2023-03-28 씨젠 인크. 항-cd228 항체 및 항체-약물 컨쥬게이트
US11795238B2 (en) 2020-08-04 2023-10-24 Crispr Therapeutics Ag Anti-idiotype antibodies targeting anti-CD70 chimeric antigen receptor
US11725052B2 (en) 2020-08-18 2023-08-15 Cephalon Llc Anti-PAR-2 antibodies and methods of use thereof
WO2022043861A1 (en) 2020-08-25 2022-03-03 Crispr Therapeutics Ag Anti-idiotype antibodies targeting anti-bcma chimeric antigen receptor
EP4208474A2 (de) 2020-09-01 2023-07-12 Takeda Pharmaceutical Company Limited Interleukin-2-muteine und verwendungen davon
CA3192526A1 (en) 2020-09-04 2022-03-10 Rutgers, The State University Of New Jersey Sars-cov-2 vaccines and antibodies
WO2022056490A1 (en) 2020-09-14 2022-03-17 Vor Biopharma, Inc. Chimeric antigen receptors for treatment of cancer
AU2021348613B2 (en) 2020-09-28 2026-04-02 Angitia Incorporated Limited Anti-sclerostin constructs and uses thereof
US11746154B2 (en) 2020-10-09 2023-09-05 Pfizer Inc. CD1a antibodies and uses thereof
CN116472277A (zh) 2020-10-13 2023-07-21 艾维泰有限责任公司 Aav8亲和剂
US20240026344A1 (en) 2020-10-13 2024-01-25 Avitide LLC Affinity ligand libraries of three-helix bundle proteins and uses thereof
AU2021359068A1 (en) 2020-10-15 2023-06-15 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha
US20240000969A1 (en) 2020-10-21 2024-01-04 Poseida Therapeutics San Diego Compositions and methods for delivery of nucleic acids
WO2022087441A2 (en) 2020-10-23 2022-04-28 Anaptysbio, Inc. B and t lymphocyte attenuator (btla) modulators and method of using same
CA3197423A1 (en) 2020-11-04 2022-05-12 Daniel Getts Engineered chimeric fusion protein compositions and methods of use thereof
JP2023547499A (ja) 2020-11-06 2023-11-10 ノバルティス アーゲー 抗体Ｆｃ変異体
EP4243868A1 (de) 2020-11-11 2023-09-20 BioNTech SE Monoklonale antikörper gegen protein mit programmiertem tod-1 und ihre verwendung in der medizin
WO2022108931A2 (en) 2020-11-17 2022-05-27 Seagen Inc. Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
WO2022115865A2 (en) 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
US20240301086A1 (en) 2020-12-01 2024-09-12 Aptevo Research And Development Llc Tumor-associated antigens and cd3-binding proteins, related compositions, and methods
WO2022116086A1 (en) 2020-12-03 2022-06-09 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
JP7747350B2 (ja) 2020-12-11 2025-10-01 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル Ｓｆｒｐ２アンタゴニストを含む組成物及び方法
EP4259661A1 (de) 2020-12-14 2023-10-18 Novartis AG Reverse bindemittel für anti-natriuretische peptidrezeptor-1 (npr1)-antikörper und verwendungen davon
WO2022140388A1 (en) 2020-12-21 2022-06-30 Allogene Therapeutics, Inc. Protease-activating cd45-gate car
WO2022137186A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
US20240101654A1 (en) 2020-12-29 2024-03-28 Neurimmune Ag Human anti-tau antibodies
CN114685669A (zh) 2020-12-30 2022-07-01 和铂医药(苏州)有限公司 结合trop2的抗体及其用途
CN117157318A (zh) 2020-12-30 2023-12-01 免疫治疗有限公司 抗hvem抗体
EP4271998A1 (de) 2020-12-30 2023-11-08 Abbott Laboratories Verfahren zur bestimmung des sars-cov-2-antigens und anti-sars-cov-2-antikörpers in einer probe
CA3204417A1 (en) 2021-01-29 2022-08-04 Allogene Therapeutics, Inc. Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products
CN117241866A (zh) 2021-02-19 2023-12-15 艾维泰有限责任公司 Aav2亲和剂
EP4297728A1 (de) 2021-02-23 2024-01-03 Poseida Therapeutics, Inc. Zusammensetzungen und verfahren zur abgabe von nukleinsäuren
EP4298205A1 (de) 2021-02-23 2024-01-03 Poseida Therapeutics, Inc. Genetisch modifizierte induzierte pluripotente stammzellen und verfahren zur verwendung davon
WO2022187270A1 (en) 2021-03-01 2022-09-09 Xilio Development, Inc. Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
EP4301781A1 (de) 2021-03-01 2024-01-10 Xilio Development, Inc. Kombination von maskierten ctla4 und pd1/pdl1-antikörpern zur behandlung von krebs
WO2022187663A1 (en) 2021-03-04 2022-09-09 Allogene Therapeutics, Inc. Fasl expression and fasr gene knockout to protect therapeutic cells from allogeneic rejection and activation-induced cell death
WO2022187671A1 (en) 2021-03-04 2022-09-09 Poseida Therapeutics, Inc. Compositions and methods for the treatment of hemophilia
JP2024509191A (ja) 2021-03-05 2024-02-29 ダイナミキュア バイオテクノロジー エルエルシー 抗ｖｉｓｔａ構築物およびその使用
MX2023010705A (es) 2021-03-12 2023-11-22 Janssen Biotech Inc Método seguro y eficaz para tratar la artritis psoriásica con el anticuerpo específico anti-il23.
BR112023018400A2 (pt) 2021-03-12 2023-12-12 Janssen Biotech Inc Método para tratamento de pacientes de artrite psoriática com resposta inadequada à terapia de tnf com anticorpo específico anti-il23
WO2022195504A1 (en) 2021-03-19 2022-09-22 Pfizer Inc. Method of treating osteoarthritis pain with an anti ngf antibody
KR20230159476A (ko) 2021-03-23 2023-11-21 킹즈 컬리지 런던 NKG2D, CXCR2 및 dap10/dap12 융합 폴리펩티드를 포함하는 조성물 및 이의 사용 방법
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
EP4314049A1 (de) 2021-03-25 2024-02-07 Dynamicure Biotechnology LLC Anti-igfbp7-konstrukte und verwendungen davon
JP2024511189A (ja) 2021-03-26 2024-03-12 ビオンテック・ソシエタス・エウロパエア がんの処置における抗ｃａ１９－９抗体およびｆｏｌｆｉｒｉｎｏｘを用いた組合せ療法。
CA3212948A1 (en) 2021-03-26 2022-09-29 David M. Hilbert Multifunctional immune cell therapies
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
CA3214853A1 (en) 2021-04-09 2022-10-13 Celidex Therapeutics, Inc. Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
AU2022272235A1 (en) 2021-05-11 2023-12-21 Create Medicines, Inc. Methods and compositions for genomic integration
AR125852A1 (es) 2021-05-12 2023-08-16 Crispr Therapeutics Ag Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en tratamiento de tumores sólidos
WO2022238962A1 (en) 2021-05-12 2022-11-17 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies
JP2024522213A (ja) 2021-06-14 2024-06-11 アルジェニクス ビーブイ 抗ｉｌ－９抗体及びその使用方法
JP2024526090A (ja) 2021-06-15 2024-07-17 アロジーン セラピューティクス，インコーポレイテッド 同種ｃａｒ ｔ細胞の持続性を延長するための宿主ｃｄ７０＋アロ反応性細胞の選択的標的化
WO2022262959A1 (en) 2021-06-15 2022-12-22 Astellas Pharma Europe Bv Bispecific binding agents binding to cldn18.2 and cd3
EP4355785A1 (de) 2021-06-17 2024-04-24 Amberstone Biosciences, Inc. Anti-cd3-konstrukte und verwendungen davon
CN117480183A (zh) 2021-06-18 2024-01-30 正大天晴药业集团股份有限公司 抗il-36r抗体及其用途
JP2024527551A (ja) 2021-06-29 2024-07-25 シージェン インコーポレイテッド 非フコシル化抗ｃｄ７０抗体及びｃｄ４７アンタゴニストの組み合わせを用いるがんを処置する方法
IL309987A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-IL12/IL23 antibody compositions
AU2022308201A1 (en) 2021-07-09 2024-02-22 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
IL309997A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions
EP4370211A1 (de) 2021-07-14 2024-05-22 Seagen Inc. Antikörpermaskierende domänen
WO2023007374A1 (en) 2021-07-27 2023-02-02 Pfizer Inc. Method of treatment of cancer pain with tanezumab
WO2023010118A1 (en) 2021-07-29 2023-02-02 Vor Biopharma Inc. Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
MX2024002150A (es) 2021-08-20 2024-03-08 Intervet Int Bv Anticuerpos y proteinas de fusion de igg con una semivida prolongada.
MX2024002149A (es) 2021-08-20 2024-03-08 Intervet Int Bv Proteinas de fusion para tratar la dermatitis atopica.
WO2023049825A1 (en) 2021-09-24 2023-03-30 Seagen Inc. Improved antibody masking domains
EP4413141A1 (de) 2021-10-04 2024-08-14 Poseida Therapeutics, Inc. Transposonzusammensetzungen und verfahren zur verwendung davon
KR20240099249A (ko) 2021-10-04 2024-06-28 포세이다 테라퓨틱스, 인크. 트랜스포사제 및 이의 용도
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之ｐｄ－ｌ１結合多肽
AU2022367525A1 (en) 2021-10-15 2024-05-02 Amgen Inc. Activatable polypeptide complex
JP2024539650A (ja) 2021-10-15 2024-10-29 シートムエックス セラピューティクス，インコーポレイテッド 活性化可能なポリペプチド複合体
WO2023064955A1 (en) 2021-10-15 2023-04-20 Cytomx Therapeutics, Inc. Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
IL312110A (en) 2021-10-29 2024-06-01 Seagen Inc Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
KR20240099352A (ko) 2021-10-29 2024-06-28 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 크론병을 치료하는 방법
WO2023079430A1 (en) 2021-11-02 2023-05-11 Pfizer Inc. Methods of treating mitochondrial myopathies using anti-gdf15 antibodies
WO2023077343A1 (en) 2021-11-04 2023-05-11 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2023081752A1 (en) 2021-11-04 2023-05-11 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
EP4433501A1 (de) 2021-11-15 2024-09-25 Janssen Biotech, Inc. Verfahren zur behandlung von morbus crohn mit anti-il23-spezifischem antikörper
JP2024540480A (ja) 2021-11-17 2024-10-31 ディスク・メディシン・インコーポレイテッド 腎臓疾患の貧血を処置する方法
WO2023091958A1 (en) 2021-11-17 2023-05-25 Altrubio Inc. Methods of using anti-psgl-1 antibodies in combination with jak inhibitors to treat t-cell mediated inflammatory diseases or cancers
WO2023094980A1 (en) 2021-11-23 2023-06-01 Fondazione Toscana Life Sciences Antibodies to coronavirus
WO2023095000A1 (en) 2021-11-23 2023-06-01 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
US20260070974A1 (en) 2021-11-25 2026-03-12 Nona Biosciences (Suzhou) Co., Ltd. Anti-siglec-15 antibody and use thereof
WO2023100153A1 (en) 2021-12-03 2023-06-08 Crispr Therapeutics Ag Use of anti-cd70 antibodies for identifying subjects susceptible for treatment with nk cell-based anti-cd70 therapy
GB202118201D0 (en) 2021-12-15 2022-01-26 King S College London Engineered immune cell
EP4448571A1 (de) 2021-12-16 2024-10-23 Intervet International B.V. Caninisierte antikörper gegen den interleukin-31-rezeptor alpha ii von hunden
WO2023111157A1 (en) 2021-12-16 2023-06-22 Intervet International B.V. Caninized and felinized antibodies to human ngf
WO2023122327A2 (en) 2021-12-24 2023-06-29 Avitide LLC Chi domain affinity ligands and agents
CA3248410A1 (en) 2022-01-14 2023-07-20 Saccharo, Inc. DE-N-ACETYLATED POLYSIALIC ACID BINDING AGENT (DPSA) AND ITS METHOD OF USE
AU2023210287A1 (en) 2022-01-21 2024-09-05 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
US20250304911A1 (en) 2022-02-02 2025-10-02 Pfizer Inc. Cysteine prototrophy
US20250115675A1 (en) 2022-02-08 2025-04-10 Amgen Inc. Codon-optimized nucleic acids encoding ocrelizumab
WO2023153876A1 (ko) 2022-02-10 2023-08-17 주식회사 아피셀테라퓨틱스 Cd40l에 특이적으로 결합하는 스테핀 a 단백질 변이체 및 이의 용도
GB202201927D0 (en) 2022-02-14 2022-03-30 Kings College Artificial microrna construct
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
WO2023164573A1 (en) 2022-02-23 2023-08-31 Poseida Therapeutics, Inc. Genetically modified cells and methods of use thereof
EP4482523A1 (de) 2022-02-23 2025-01-01 Alector LLC Verfahren zur verwendung von anti-trem2-antikörpern
AU2023223523A1 (en) 2022-02-28 2024-09-26 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
US20240117030A1 (en) 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
WO2024026472A2 (en) 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
CA3260121A1 (en) 2022-03-25 2023-09-28 Les Laboratoires Servier ANTI-GAL3 ANTIBODIES AND COMPOSITIONS
CA3244596A1 (en) 2022-03-29 2023-10-05 Allogene Therapeutics, Inc. Chimeric switch receivers for converting immunoactive signals into stimulation signals
WO2023187657A1 (en) 2022-03-30 2023-10-05 Novartis Ag Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies
WO2023193239A1 (en) 2022-04-08 2023-10-12 Peter Peizhi Luo Anti-cd28 antibodies and methods of use thereof
KR20250007603A (ko) 2022-04-27 2025-01-14 아납티스바이오, 아이엔씨. B 및 t 림프구 감쇠제(btla) 조절제 및 이를 사용하는 방법
JP2025514858A (ja) 2022-04-29 2025-05-09 アストラゼネカ・ユーケイ・リミテッド ＳＡＲＳ－ＣｏＶ－２抗体、及びその使用方法
WO2023213960A1 (en) 2022-05-06 2023-11-09 Genmab A/S Methods of treating cancer with anti-tissue factor antibody-drug conjugates
WO2023218320A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
US20240059799A1 (en) 2022-05-11 2024-02-22 Pfizer Inc. Anti-tl1a antibodies and methods of use thereof
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
US11932693B2 (en) 2022-05-12 2024-03-19 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
EP4526342A1 (de) 2022-05-18 2025-03-26 Janssen Biotech, Inc. Verfahren zur bewertung und behandlung von psoriasisarthritis mit il23-antikörper
AU2023276940A1 (en) 2022-05-26 2024-12-12 Pfizer Inc. Anti-tnfr2 antibodies and methods of use thereof
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
CA3254800A1 (en) 2022-05-31 2023-12-07 The Brigham And Women's Hospital, Inc. Anti-BMP9 antibodies and their methods of use
CA3258000A1 (en) 2022-06-15 2023-12-21 argenx BV FCRN/ANTIGEN BINDING MOLECULES AND METHODS OF USE
WO2023242769A1 (en) 2022-06-17 2023-12-21 Pfizer Inc. Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof
CA3262035A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. BIOLOGICALLY ENGINEERED IMPROVED MATERIAL AND PAIRING METHODS FOR VARIABLE ANTIGEN-BINDING REGIONS
JP2025525779A (ja) 2022-07-29 2025-08-07 アロジーン セラピューティクス，インコーポレイテッド 免疫細胞の認識を低減させるために遺伝子発現が低下した、操作された細胞
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
EP4562022A1 (de) 2022-07-29 2025-06-04 Repligen Corporation Affinitätsagent mit einem ligand zur bindung von vce und mit seq id no: 1
WO2024028773A1 (en) 2022-08-03 2024-02-08 Pfizer Inc. Anti- il27r antibodies and methods of use thereof
JP2025528163A (ja) 2022-08-11 2025-08-26 ポセイダ セラピューティクス，インコーポレイティド キメラｃｄ８－アルファ補助受容体組成物及び使用方法
WO2024038187A1 (en) 2022-08-19 2024-02-22 Medimmune Limited Assay for detection of il-33
WO2024054929A1 (en) 2022-09-07 2024-03-14 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
AU2023367039A1 (en) 2022-10-25 2025-05-15 Ablexis, Llc Anti-cd3 antibodies
CN120435319A (zh) 2022-11-03 2025-08-05 思进公司 抗-avb6抗体和抗体-药物缀合物及其在癌症治疗中的用途
JP2025537224A (ja) 2022-11-07 2025-11-14 アナプティスバイオ インコーポレイティッド Ｃｄ１２２結合剤およびその使用方法
WO2024107731A2 (en) 2022-11-14 2024-05-23 Ablexis, Llc Anti-pd-l1 antibodies
US20240199734A1 (en) 2022-11-22 2024-06-20 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
WO2024150074A2 (en) 2023-01-13 2024-07-18 Takeda Pharmaceutical Company Limited Coronavirus antibodies and therapeutic uses thereof
JP2026504862A (ja) 2023-01-18 2026-02-10 ファイザー・インク 呼吸器疾患に対するワクチン
JP2026503550A (ja) 2023-01-20 2026-01-29 ポセイダ セラピューティクス，インコーポレイティド リピドイド化合物ならびに関連する組成物および使用
WO2024155931A1 (en) 2023-01-20 2024-07-25 Poseida Therapeutics, Inc. Lipidoid compounds and related compositions and uses
IT202300000924U1 (it) 2023-01-23 2024-12-22 Philomena Dove Cucitura all-up leggins seamless
JP2026505276A (ja) 2023-01-31 2026-02-13 ユニバーシティ オブ ロチェスター Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ感染症を治療するための免疫チェックポイント遮断療法
EP4665459A1 (de) 2023-02-13 2025-12-24 Intervet International B.V. Antikörper gegen hunde il-13
JP2026506599A (ja) 2023-02-13 2026-02-25 インターベット インターナショナル ベー． フェー． イヌｉｌ－４に対するイヌ抗体
AU2024224841A1 (en) 2023-02-21 2025-08-21 Poseida Therapeutics, Inc. Aav piggybac transposon polynucleotide compositions and methods of use therefor
EP4669745A1 (de) 2023-02-21 2025-12-31 Poseida Therapeutics, Inc. Zusammensetzungen und verfahren zur genomeditierung
JP2026507648A (ja) 2023-02-21 2026-03-04 ポセイダ セラピューティクス，インコーポレイティド ゲノム編集のための組成物及び方法
EP4673469A1 (de) 2023-03-02 2026-01-07 Alloy Therapeutics, Inc. Anti-cd22-antikörper und verwendungen davon
CN121219315A (zh) 2023-03-03 2025-12-26 塞德斯医疗公司 抗干细胞因子(scf)和抗胸腺基质淋巴细胞生成素(tslp)抗体及双特异性构建体
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
FR3147278A1 (fr) 2023-03-31 2024-10-04 Avacta Life Sciences Limited Polypeptides de liaison au tnfr2 et procedes d'utilisation
EP4688825A1 (de) 2023-03-31 2026-02-11 AffyXell Therapeutics Co., Ltd. Tnfr2-bindende polypeptide und verfahren zur verwendung
KR20250173518A (ko) 2023-04-05 2025-12-10 포세이다 테라퓨틱스, 인크. 트랜스포사제 폴리뉴클레오티드 및 그의 용도
KR20250167671A (ko) 2023-04-05 2025-12-01 포세이다 테라퓨틱스, 인크. 키메라 트랜스포사제 및 그의 용도
CN121219409A (zh) 2023-04-05 2025-12-26 波西达治疗公司 转座酶及其用途
CA3205511A1 (en) 2023-04-19 2025-03-17 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2024218650A1 (en) 2023-04-19 2024-10-24 Pfizer Inc. Lilrb1 and lilrb2 antibodies and methods of use thereof
KR20260013515A (ko) 2023-04-24 2026-01-28 머크 샤프 앤드 돔 엘엘씨 Trop2 결합제 및 그의 접합체
EP4455161A1 (de) 2023-04-24 2024-10-30 ONO Pharmaceutical Co., Ltd. Vom menschen abgeleitete antikörper gegen das collapsin response mediator protein 2 (crmp2)
AU2024269156A1 (en) 2023-05-09 2026-01-08 Astrazeneca Ab Bispecific anti-pseudomonas antibodies with modified fc regions and methods of use thereof
WO2024233804A1 (en) 2023-05-10 2024-11-14 Poseida Therapeutics, Inc. Transposases and uses thereof
WO2024235175A1 (zh) 2023-05-12 2024-11-21 智泽童康(广州)生物科技有限公司 抗cldn6抗体及其用途
IL324556A (en) 2023-05-19 2026-01-01 Servier Lab Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof
WO2024243594A1 (en) 2023-05-25 2024-11-28 Anaptysbio, Inc. Btla agonist for mudulation of dendritic cells
IL325757A (en) 2023-07-12 2026-03-01 Saccharo Inc N-acyl-free polyacyl acid linking agent, conjugates, and method for using the same
IT202300015579A1 (it) 2023-07-25 2025-01-25 Fond Toscana Life Sciences Anticorpi contro covid-19 e altri coronavirus umani
WO2025030010A1 (en) 2023-08-01 2025-02-06 Vor Biopharma Inc. Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof
WO2025036848A1 (en) 2023-08-11 2025-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Anti-muc16 antibodies and uses thereof
WO2025038362A1 (en) 2023-08-11 2025-02-20 Merck Sharp & Dohme Llc Monovalent interleukin 12 (il-12) heterodimeric fc proteins
WO2025038492A1 (en) 2023-08-11 2025-02-20 Abalytics Oncology, Inc. Anti-ctla-4 antibodies and related binding molecules and methods and uses thereof
WO2025046393A1 (en) 2023-08-25 2025-03-06 Fondazione Per L’Istituto Oncologico Di Ricerca (Ior) Reagents against human endogenous retroviruses to target cancer cells
WO2025049925A2 (en) 2023-09-01 2025-03-06 Poseida Therapeutics, Inc. Lipidoid compounds and related compositions and uses
WO2025049905A1 (en) 2023-09-01 2025-03-06 Gennao Bio, Inc. Dnase co-expression in host cells
US20250101101A1 (en) 2023-09-01 2025-03-27 iTeos Belgium SA Anti-trem2 antibodies and methods of use
EP4530295A3 (de) 2023-09-07 2025-05-28 argenx BV Fcrn-antagonisten und verfahren zur verwendung
WO2025064507A1 (en) 2023-09-19 2025-03-27 Poseida Therapeutics, Inc. Compositions and methods for integration of viral vectors
US20250109187A1 (en) 2023-09-28 2025-04-03 Novavax, Inc. ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19
WO2025076341A1 (en) 2023-10-05 2025-04-10 Janssen Biotech, Inc. Improved methods in lentiviral manufacturing for production of car-t cell drug products
TW202535938A (zh) 2023-10-17 2025-09-16 德商拜恩迪克公司 專一性結合ｃｄ３之抗原結合蛋白及其醫藥用途
WO2025083173A1 (en) 2023-10-17 2025-04-24 Linnane Pharma Ab Bacterial lon protease domains and their use in therapy
WO2025082594A1 (en) 2023-10-17 2025-04-24 BioNTech SE Antigen binding proteins specifically binding to cd3 and their use in medicine
WO2025096560A1 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Engineered cells
US20250154287A1 (en) 2023-11-10 2025-05-15 Pfizer Inc. ANTI-MIGIS-alpha ANTIBODIES AND METHODS OF USE THEREOF
WO2025106663A1 (en) 2023-11-15 2025-05-22 Slate Bio, Inc. Interleukin-33 variants, compositions and uses thereof
WO2025106685A1 (en) 2023-11-15 2025-05-22 Slate Bio, Inc. Interleukin-2 superkine and interleukin-33, compositions and uses thereof
WO2025104668A1 (en) 2023-11-17 2025-05-22 Pfizer Inc. Anti-gastric inhibitory polypeptide receptor (gipr) antibodies and antibody conjugates for the treatment of metabolic disorders
TW202523694A (zh) 2023-11-17 2025-06-16 中國大陸商上海藥明生物技術有限公司 抗muc16抗體及其用途
WO2025111402A1 (en) 2023-11-21 2025-05-30 Board Of Regents Of The University Of Nebraska Anti-amyloid beta antibodies and related compositions and methods thereof
IT202300026115A1 (it) 2023-12-06 2025-06-06 Fond Per L’Istituto Oncologico Di Ricerca Ior Una strategia basata su anticorpi che mira ad erg oncogenico attivato nel cancro alla prostata
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025133694A1 (en) 2023-12-20 2025-06-26 argenx BV Fcrn/hsa-binding molecules and methods of use
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法
WO2025133186A1 (en) 2023-12-22 2025-06-26 OncoC4, Inc. Anti-ctla-4 antibody for treatment of patients with prostate cancer and combination therapy with a radioligand therapeutic agent
WO2025155877A2 (en) 2024-01-18 2025-07-24 The Regents Of The University Of California Antibodies binding to pad4 and uses thereof
WO2025155971A1 (en) 2024-01-19 2025-07-24 Immunomic Therapeutics, Inc Anti-activin receptor 1c (alk-7) receptor antibodies
WO2025157132A1 (en) 2024-01-23 2025-07-31 Wuxi Biologics (Shanghai) Co., Ltd. Multispecific antibodies targeting cd3, cd19 and cd20 and uses thereof
WO2025160275A1 (en) 2024-01-24 2025-07-31 Arrowhead Pharmaceuticals, Inc. Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof
WO2025160432A1 (en) 2024-01-26 2025-07-31 Poseida Therapeutics, Inc. Methods and compositions for enhancing in vivo persistence and potency of cell therapy
TW202545567A (zh) 2024-01-30 2025-12-01 美商思進公司 抗ｐｄ－ｌ１抗體和抗體－藥物共軛體及彼等在治療癌症的用途
WO2025166042A1 (en) 2024-01-31 2025-08-07 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2025166045A1 (en) 2024-01-31 2025-08-07 Alector Llc β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
WO2025166040A1 (en) 2024-01-31 2025-08-07 Alector Llc Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
WO2025166077A1 (en) 2024-01-31 2025-08-07 Alector Llc Compositions comprising progranulin and uses thereof
US20250269024A1 (en) 2024-02-05 2025-08-28 Legend Biotech Usa Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2025171237A1 (en) 2024-02-08 2025-08-14 Poseida Therapeutics, Inc. Lipidoid compounds and related compositions and uses
TW202600608A (zh) 2024-02-27 2026-01-01 美商必治妥美雅史谷比公司 抗ｃｅａｃａｍ５抗體及其用途
US20250361297A1 (en) 2024-03-12 2025-11-27 Adaptam Therapeutics, S.L. Anti- siglec-15 binding molecules and methods of use
US20250339527A1 (en) 2024-03-12 2025-11-06 Legend Biotech Usa Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2025196207A1 (en) 2024-03-20 2025-09-25 King's College London Compositions and methods for use in depleting senescent cells and treating aging
WO2025199352A2 (en) 2024-03-20 2025-09-25 Juno Therapeutics, Inc. Antibodies specific for solute carrier family 34 member 2 (slc34a2)
CA3249015A1 (en) 2024-03-20 2025-10-31 Janssen Biotech, Inc. Methods of treating crohn’s disease with anti-il23 specific antibody
WO2025201659A1 (en) 2024-03-28 2025-10-02 BioNTech SE Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment
EP4635983A1 (de) 2024-04-15 2025-10-22 Ymmunobio AG Neuartiger antikörper mit spezifischer bindung an nptxr und verwendung davon
WO2025221789A1 (en) 2024-04-16 2025-10-23 Poseida Therapeutics, Inc. Compositions and methods for use in car/tcr cell therapies
WO2025235515A1 (en) 2024-05-07 2025-11-13 Cytomx Therapeutics, Inc. Activatable polypeptide complex formulations
WO2025233867A1 (en) 2024-05-10 2025-11-13 Adaptam Therapeutics, S.L. Anti-siglec-9 antibodies and uses thereof
WO2025240670A2 (en) 2024-05-15 2025-11-20 Abalytics Oncology, Inc. Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
WO2025257715A1 (en) 2024-06-12 2025-12-18 Seagen Inc. Anti-ceacam5 antibodies, antibody-drug conjugates and methods of uses thereof
US20260103510A1 (en) 2024-06-17 2026-04-16 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
WO2025262564A1 (en) 2024-06-17 2025-12-26 Pfizer Inc. Use of anti-cxcr5 antibodies
WO2025264572A1 (en) 2024-06-17 2025-12-26 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2025261951A1 (en) 2024-06-18 2025-12-26 BioNTech SE Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer
WO2026006494A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-cd3 antibodies and uses thereof
WO2026006495A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-wt1/hla-a2 antibody and uses thereof
WO2026006492A2 (en) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anti-prame/hla-a2 antibodies and uses thereof
CA3258952A1 (en) 2024-06-27 2026-03-01 Janssen Biotech, Inc. Methods of treating ulcerative colitis with anti-il23 specific antibody
WO2026027944A1 (en) 2024-07-30 2026-02-05 Sairopa B.V. Anti-sirp alpha antibody formulations and uses thereof
WO2026039642A1 (en) 2024-08-16 2026-02-19 Ardeagen Corporation Anti-mesothelin antibody conjugates and methods of use thereof
WO2026041734A1 (en) 2024-08-22 2026-02-26 Novago Therapeutics Ag Methods for treating neurological disorders using anti-nogo-a antibodies
WO2026041780A2 (en) 2024-08-23 2026-02-26 BioNTech SE Combination therapy comprising anti-ctla4 antibodies and chemotherapy for cancer treatment
WO2026057545A1 (en) 2024-09-10 2026-03-19 Neurimmune Ag Anti-sting antibodies and methods of use thereof
WO2026057739A1 (en) 2024-09-12 2026-03-19 BioNTech SE Combination therapy comprising anti-ctla4 antibodies and anti-pd-1 antibodies for platinum-resistant ovarian cancer treatment
WO2026064550A1 (en) 2024-09-19 2026-03-26 Poseida Therapeutics, Inc. Transposases and uses thereof
WO2026080393A1 (en) 2024-10-07 2026-04-16 Poseida Therapeutics, Inc. Compositions and methods for use in car cell therapies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) * 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4797359A (en) * 1983-05-10 1989-01-10 Board Of Regents, The University Of Texas System Heat shock regulated production of selected and fused proteins in yeast
AU576402B2 (en) * 1984-10-01 1988-08-25 General Hospital Corporation, The Plant cells resistant to herbicidal glutamine synthetase inhibitors
JPS62502662A (ja) * 1985-05-01 1987-10-15 ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド 外来性ｄｎａの高レベル増幅および発現
GB8601597D0 (en) * 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences

Also Published As

Publication number Publication date
JPS63502955A (ja) 1988-11-02
GB8601597D0 (en) 1986-02-26
JPH0732712B2 (ja) 1995-04-12
US5122464A (en) 1992-06-16
CA1338901C (en) 1997-02-11
US5827739A (en) 1998-10-27
AU6893587A (en) 1987-08-14
WO1987004462A1 (en) 1987-07-30
AU599081B2 (en) 1990-07-12
EP0256055B1 (de) 1991-08-28
DE3772485D1 (de) 1991-10-02
EP0256055A1 (de) 1988-02-24
US5770359A (en) 1998-06-23

Similar Documents

Publication Publication Date Title
ATE66693T1 (de) Rekombinante dns-sequenzen, diese enthaltende vektoren und verfahren zur verwendung derselben.
ES2009238A6 (es) Metodo para producir proteinas de mycobacterium tuberculosis y peptidos antigenicos de las mismas.
DE3854952D1 (de) Mykobakterielle rekombinanten und peptide
DE69534785D1 (en) Pflanzen lysophosphatidesäure-acyltransferase
DE3752379D1 (de) Verfahren zur Herstellung von Proteinprodukten in Aspergillus-Oryzae und in Aspergillus zu verwendender Promotor
EP1092771A3 (de) Tetracyclin-regulierte Transcriptionsmodulatoren
LTIP828A (en) Nucleic acid fragment which codes for human proapolipoprotein a-1
ATE46536T1 (de) Verfahren zur herstellung von reifen proteinen in wirtzellen von wirbeltieren.
IL173399A0 (en) Circular dna molecule with conditional origin of replication which contains nucleic acid of interest and selection marker but does not encode its replication initiation protein, method for preparing the same and use thereof in gene therapy
NO20015587L (no) Ekspresjon og eksport av interferon-<alfa> proteiner som Fc fusjonsproteiner
AU7833494A (en) Enhanced expression in plants using non-translated leader sequences
ATE42114T1 (de) Mikrobiologisch hergestelltes interferon alpha2(arg), dna-sequenz, die fuer dieses interferon codiert, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung.
UA42726C2 (uk) Виділений поліпептид, здатний зв'язувати flt3, виділений полінуклеотид, який кодує поліпептид, здатний зв'язувати flt3 (варіанти),виділений полінуклеотид, здатний гібридизуватися з ним (варіанти), вектор експресії (варіанти), лінія клітин- хазяїв (варіанти), спосіб одержання поліпептиду, здатного зв'язувати flt3 (варіанти), фармацевтична композиція, спосіб проведення аутологічної трансплантації хворому, який отримує цитовідновлювальну терапію, середовище для розмноження гемопоетичних клітин, спосіб трансфекції екзогенного гена в недиференційовану "ранню" гемопоетичну клітину, спосіб переносу екзогенного гена ссавцю, спосіб стимуляції проліферації т-клітин у ссавця, спосіб стимуляції проліферації клітин еритроїдного направлення диференціювання в селезінці ссавця, спосіб лікування хворого, який має симптоми мієлодиспластичного синдрому, спосіб лікування хворого, який має симптоми анемії, спосіб лікування хворого, який має симптоми синдрому набутого імунодефіциту, спосіб відокремлення клітин, які мають рецептор flt3 на їх поверхні, від суміші клітин в суспензії, антитіло, імунореактивне з поліпептидом, здатним зв'язувати flt3
DE69333815D1 (de) Gentranskription und ionisierende strahlung: methoden und zusammensetzungen
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
DK163187C (da) Fremgangsmaader til fremstilling af humant immuninterferon (gamma-interferon) samt dna-fragmenter, rekombinante klonings- og udtrykkelsesvektorer og rekombinante mikroorganismer og cellekulturer til anvendelse herved
ATE45382T1 (de) Biosynthetisch hergestellter humannervenwachstumsfaktor, verfahren zu seiner herstellung, diesen faktor enthaltende zusammensetzungen, diesen faktor codierende dna- sequenz, vektoren, die diese sequenz enthalten und dadurch transformierte wirtszellen.
DE69026716D1 (de) Nukleinsäurefragmente von einem genom eines geeigneten mykobakteriums, ihre verwendung zur diagnose von mykobakterieninfektionen sowie diese fragmente enthaltende plasmide
ATE89317T1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
Weinstein Comparative studies on the genetic code
NZ334568A (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
ES2058108T3 (es) Sistema de expresion de genes.
ATE288488T1 (de) Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen
ATE43139T1 (de) Klonierungs- und expressionsvektoren fuer gammainterferon, transformierte bakterien und verfahren zur herstellung von gamma-interferon.
EP0196223A3 (en) Dedicated ribosomes and their use in producing protein in cell culture

Legal Events

Date Code Title Description
EELA Cancelled due to lapse of time